Fuse Medical, Inc 10-Q for FY2020 Q3
Fuse Medical, Inc. (FZMD)
About this 10-Q
Fuse Medical, Inc filed this 10-Q on November 16, 2020, covering the quarter ended September 30, 2020 (FY2020 Q3).
Headline figures
Quarter ended September 30, 2020, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $5.74M
- up 0.4% from $5.72M a year earlier
- Net income
- $80.48K
- compared with a net loss of $4.06M a year earlier
- Diluted EPS
- $0.00
- compared with -$0.06 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended: September 30, 2020
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number: 000-10093
Fuse Medical, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
59-1224913 |
|
(State or other jurisdiction of |
|
(I.R.S. Employer |
|
incorporation or organization) |
|
Identification No.) |
|
|
|
|
|
1565 N. Central Expressway, Suite 220, Richardson, TX |
|
75080 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(469) 862-3030
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer |
☐ |
|
Accelerated filer |
☐ |
|
Non-accelerated filer |
☐ |
|
Smaller reporting company |
☒ |
|
Emerging growth company |
☐ |
|
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock |
|
FZMD |
|
OTCPink |
Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date: As of November 5, 2020, 73,124,458 shares of the registrant’s common stock, $0.01 par value, were outstanding.
1
FUSE MEDICAL, INC.
FORM 10-Q
INDEX
2
Item 1. Condensed Consolidated Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS
(in dollars, except share data)
|
|
|
September 30, 2020 |
|
|
December 31, 2019 |
|
||
|
|
|
(Unaudited) |
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash |
|
$ |
1,538,888 |
|
|
$ |
1,099,310 |
|
|
Accounts receivable, net of allowance of $801,685 and $615,278, respectively |
|
|
3,215,069 |
|
|
|
5,249,653 |
|
|
Inventories |
|
|
6,982,916 |
|
|
|
7,855,887 |
|
|
Prepaid expenses and other current assets |
|
|
34,959 |
|
|
|
39,850 |
|
|
Total current assets |
|
|
11,771,832 |
|
|
|
14,244,700 |
|
|
Property and equipment, net |
|
|
25,255 |
|
|
|
32,639 |
|
|
Long term accounts receivable, net of allowance of $1,491,361 and $728,000, respectively |
|
|
2,069,689 |
|
|
|
924,646 |
|
|
Intangible assets, net |
|
|
1,150,713 |
|
|
|
1,206,620 |
|
|
Goodwill |
|
|
1,972,886 |
|
|
|
1,972,886 |
|
|
Total assets |
|
$ |
16,990,375 |
|
|
$ |
18,381,491 |
|
|
Liabilities and Stockholders' Equity (Accumulated Deficit) |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2,343,483 |
|
|
$ |
2,752,854 |
|
|
Accrued expenses |
|
|
3,521,939 |
|
|
|
3,302,904 |
|
|
Convertible notes payable - related parties |
|
|
150,000 |
|
|
|
150,000 |
|
|
Paycheck Protection Program loan |
|
|
361,400 |
|
|
|
— |
|
|
Senior secured revolving credit facility |
|
|
1,038,352 |
|
|
|
1,752,501 |
|
|
Total current liabilities |
|
|
7,415,174 |
|
|
|
7,958,259 |
|
|
Notes payable - related parties |
|
|
200,000 |
|
|
|
— |
|
|
Economic Injury Disaster Loan |
|
|
150,000 |
|
|
|
— |
|
|
Earn-out liability |
|
|
11,645,365 |
|
|
|
11,645,365 |
|
|
Total liabilities |
|
|
19,410,539 |
|
|
|
19,603,624 |
|
|
Commitments and contingencies |
|
|
— |
|
|
|
— |
|
|
Stockholders' equity (Accumulated deficit) |
|
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value; 20,000,000 shares authorized, no shares issued and outstanding |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.01 par value; 100,000,000 shares authorized, 73,124,458 shares issued and outstanding as of September 30, 2020 and December 31, 2019 |
|
|
731,245 |
|
|
|
731,245 |
|
|
Additional paid-in capital |
|
|
1,071,350 |
|
|
|
642,435 |
|
|
Accumulated deficit |
|
|
(4,222,759 |
) |
|
|
(2,595,813 |
) |
|
Total stockholders' equity |
|
|
(2,420,164 |
) |
|
|
(1,222,133 |
) |
|
Total liabilities and stockholders' equity |
|
$ |
16,990,375 |
|
|
$ |
18,381,491 |
|
See notes to unaudited condensed consolidated financial statements.
F-1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in dollars, except share data)
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
||||||||||
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenues |
$ |
5,738,662 |
|
|
$ |
5,716,344 |
|
|
$ |
14,385,831 |
|
|
$ |
15,562,928 |
|
|
Cost of revenues |
|
2,043,722 |
|
|
|
4,787,939 |
|
|
|
5,823,281 |
|
|
|
8,987,196 |
|
|
Gross profit |
|
3,694,940 |
|
|
|
928,405 |
|
|
|
8,562,550 |
|
|
|
6,575,732 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general, administrative and other |
|
1,379,385 |
|
|
|
2,263,964 |
|
|
|
5,021,632 |
|
|
|
6,604,066 |
|
|
Commissions |
|
2,185,487 |
|
|
|
1,741,770 |
|
|
|
4,996,843 |
|
|
|
3,752,295 |
|
|
Depreciation and amortization |
|
23,312 |
|
|
|
25,596 |
|
|
|
84,047 |
|
|
|
76,916 |
|
|
Total operating expenses |
|
3,588,184 |
|
|
|
4,031,330 |
|
|
|
10,102,522 |
|
|
|
10,433,277 |
|
|
Operating income\(loss) |
|
106,756 |
|
|
|
(3,102,925 |
) |
|
|
(1,539,972 |
) |
|
|
(3,857,545 |
) |
|
Other expense: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
20,611 |
|
|
|
34,900 |
|
|
|
75,633 |
|
|
|
88,362 |
|
|
Total other expense |
|
20,611 |
|
|
|
34,900 |
|
|
|
75,633 |
|
|
|
88,362 |
|
|
Net income\(loss) before tax |
|
86,145 |
|
|
|
(3,137,825 |
) |
|
|
(1,615,605 |
) |
|
|
(3,945,907 |
) |
|
Income tax expense |
|
5,661 |
|
|
|
926,517 |
|
|
|
11,341 |
|
|
|
771,582 |
|
|
Net income\(loss) |
$ |
80,484 |
|
|
$ |
(4,064,342 |
) |
|
$ |
(1,626,946 |
) |
|
$ |
(4,717,489 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income\(loss) per common share - basic |
$ |
0.00 |
|
|
$ |
(0.06 |
) |
|
$ |
(0.02 |
) |
|
$ |
(0.07 |
) |
|
Net income\(loss) per common share - diluted |
$ |
0.00 |
|
|
$ |
(0.06 |
) |
|
$ |
(0.02 |
) |
|
$ |
(0.07 |
) |
|
Weighted average number of common shares outstanding - basic |
|
70,221,566 |
|
|
|
70,221,566 |
|
|
|
70,221,566 |
|
|
|
70,221,566 |
|
|
Weighted average number of common shares outstanding - diluted |
|
74,999,458 |
|
|
|
70,221,566 |
|
|
|
70,221,566 |
|
|
|
70,221,566 |
|
See notes to unaudited condensed consolidated financial statements.
F-2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(unaudited)
(in dollars, except share data)
|
|
|
Common Stock |
|
|
Additional Paid-In |
|
|
Retained Earnings/ |
|
|
|
|
|
|||||||
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
(Deficit) |
|
|
Total |
|
|||||
|
Balance, December 31, 2019 |
|
|
73,124,458 |
|
|
$ |
731,245 |
|
|
$ |
642,435 |
|
|
$ |
(2,595,813 |
) |
|
$ |
(1,222,133 |
) |
|
Stock compensation expense |
|
|
- |
|
|
|
- |
|
|
|
428,915 |
|
|
|
- |
|
|
|
428,915 |
|
|
Net loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(1,626,946 |
) |
|
|
(1,626,946 |
) |
|
Balance, September 30, 2020 |
|
|
73,124,458 |
|
|
$ |
731,245 |
|
|
$ |
1,071,350 |
|
|
$ |
(4,222,759 |
) |
|
$ |
(2,420,164 |
) |
____________________________________________________________________________________________________________
|
|
|
Common Stock |
|
|
Additional Paid-In |
|
|
Retained Earnings/ |
|
|
|
|
|
|||||||
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
(Deficit) |
|
|
Total |
|
|||||
|
Balance, December 31, 2018 |
|
|
74,600,181 |
|
|
$ |
746,002 |
|
|
$ |
- |
|
|
$ |
720,682 |
|
|
$ |
1,466,684 |
|
|
Stock compensation expense |
|
|
- |
|
|
|
- |
|
|
|
487,524 |
|
|
|
- |
|
|
|
487,524 |
|
|
Net loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(4,717,489 |
) |
|
|
(4,717,489 |
) |
|
Balance, September 30, 2019 |
|
|
74,600,181 |
|
|
$ |
746,002 |
|
|
$ |
487,524 |
|
|
$ |
(3,996,807 |
) |
|
$ |
(2,763,281 |
) |
See notes to unaudited condensed consolidated financial statements.
F-3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
|
|
|
For the Nine Months Ended September 30, |
|
|||||
|
|
|
2020 |
|
|
2019 |
|
||
|
Cash flows from operating activities |
|
|
|
|
|
|
|
|
|
Net income\(loss) |
|
$ |
(1,626,946 |
) |
|
$ |
(4,717,489 |
) |
|
Adjustments to reconcile net loss to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
84,047 |
|
|
|
76,916 |
|
|
Stock based compensation |
|
|
428,915 |
|
|
|
487,524 |
|
|
Provision for bad debts and discounts |
|
|
186,407 |
|
|
|
702,811 |
|
|
Provision for long term accounts receivable |
|
|
763,361 |
|
|
|
376,826 |
|
|
Deferred income tax expense |
|
|
- |
|
|
|
760,993 |
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
1,848,177 |
|
|
|
161,943 |
|
|
Inventories |
|
|
872,971 |
|
|
|
2,886,268 |
|
|
Prepaid expenses and other current assets |
|
|
4,891 |
|
|
|
12,188 |
|
|
Long term accounts receivable |
|
|
(1,908,403 |
) |
|
|
(774,712 |
) |
|
Accounts payable |
|
|
(409,371 |
) |
|
|
(186,823 |
) |
|
Accrued expenses |
|
|
219,035 |
|
|
|
125,458 |
|
|
Net cash provided by (used in) operating activities |
|
|
463,084 |
|
|
|
(88,097 |
) |
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
|
Purchase of property and equipment |
|
|
(20,757 |
) |
|
|
— |
|
|
Net cash used in investing activities |
|
|
(20,757 |
) |
|
|
- |
|
|
Cash flows from financing activities |
|
|
|
|
|
|
|
|
|
Payments on senior secured revolving credit facility, net |
|
|
(714,149 |
) |
|
|
275,053 |
|
|
Proceeds from Paycheck Protection Program |
|
|
361,400 |
|
|
|
— |
|
|
Proceeds from related party promissory notes |
|
|
200,000 |
|
|
- |
|
|
|
Proceeds from Economic Injury Disaster Loan |
|
|
150,000 |
|
|
|
— |
|
|
Net cash provided by (used in) financing activities |
|
|
(2,749 |
) |
|
|
275,053 |
|
|
Net increase in cash |
|
|
439,578 |
|
|
|
186,956 |
|
|
Cash - beginning of period |
|
|
1,099,310 |
|
|
|
844,314 |
|
|
Cash - end of period |
|
$ |
1,538,888 |
|
|
$ |
1,031,270 |
|
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
|
|
|
Cash paid for interest |
|
$ |
52,188 |
|
|
$ |
69,257 |
|
See notes to unaudited condensed consolidated financial statements.
F-4
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1. Nature of Operations
Overview
Fuse Medical, Inc., a Delaware corporation (the “Company”), is a manufacturer and national distributor of medical devices and surgical implants for the orthopedic market. The Company acquired CPM Medical Consultants, LLC (“CPM”) in December 2017 (the “CPM Acquisition”), in which the Company was the legal acquirer and CPM was deemed the accounting acquirer. In August 2018, the Company completed the acquisition of Palm Springs Partners, LLC d/b/a Maxim Surgical (“Maxim” and such transactions the “Maxim Acquisition”). CPM and Maxim survive as the Company’s wholly-owned subsidiaries and subsequent to the completion of each acquisition, CPM, Maxim and Company operations were consolidated.
Basis of Presentation
The interim unaudited condensed consolidated financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of the Company’s management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company’s management believes the disclosures are adequate to make the information presented not misleading.
The condensed consolidated balance sheet information as of December 31, 2019 was derived from the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2019 (“2019 Annual Report”), filed with the SEC pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on March 30, 2020. These interim unaudited condensed consolidated financial statements should be read in conjunction with the 2019 Annual Report.
The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the entire fiscal year or for any other period as the Company has historically experienced seasonal trends with greater revenue and volume between the last two calendar quarters compared to the first two calendar quarters of the year.
Going Concern
The accompanying interim unaudited condensed consolidated financial statements have been prepared as if the Company will continue as a going concern. Through September 30, 2020, the Company has accumulated losses of $4,222,759 and a stockholders’ deficit of $2,420,164. Although revenue increased by $22,318 in the third quarter of 2020 compared to the same quarter in 2019, the Company has been impacted in 2020 by restrictions as a result of the novel coronavirus SARS-CoV-2 global pandemic (“COVID-19”). At various times during the years ended December 31, 2018 and 2019 and in the first quarter ended March 31, 2020, the Company was out of compliance with one or more covenants contained in its Amended and Restated Business Loan Agreement (“RLOC”) with ZB, N.A., d/b/a Amegy Bank (“Amegy Bank”), but obtained waivers from Amegy Bank to cure the violations, resulting in reductions in the Company’s aggregate contractual borrowing limits under the RLOC. The RLOC functions as a senior secured revolving loan facility. On November 12, 2020, the Company executed a Sixth Amendment to the RLOC with Amegy Bank which extended the termination date of the RLOC until May 4, 2021. (See Note 13, “Subsequent Events”). The Company’s management has determined that these conditions and events raise substantial doubt about the ability of the Company to continue as a going concern.
The Company’s ability to continue as a going concern for at least one year beyond the date of this unaudited condensed consolidated balance sheet at September 30, 2020 is dependent upon the continued easing of restrictions imposed on elective surgeries by governmental authorities as a result of COVID-19, as well as the Company’s (i) successful execution of key branding initiatives, (ii) introduction, commercialization and sales of new proprietary products and product lines, (iii) increased sales of existing products, with strategic emphasis on direct sales to medical facilities (“Retail Cases”), and increasing the percentage of Retail Cases sold as a percentage of all cases sold by the Company (sales volume based on medical procedures in which the Company’s products are sold and used “Cases”), and (iv) continued cost reductions. Additionally, the Company will need to refinance its RLOC with Amegy Bank with a new credit facility on commercially reasonable terms, or obtain financing by May 4, 2021.
F-5
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The interim unaudited condensed consolidated financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.
Note 2. Significant Accounting Policies
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, CPM and Maxim. Intercompany transactions have been eliminated in consolidation.
Use of Estimates
The preparation of the interim unaudited condensed consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and assumptions that affect the Company’s reported amounts in the interim unaudited condensed consolidated financial statements.
Actual results could differ from those estimates. Significant estimates on the accompanying interim unaudited condensed consolidated financial statements include the allowances for doubtful accounts, valuation of inventories, the Company’s effective income tax rate, and the recoverability of deferred tax assets, which are based upon the Company management’s expectation of future taxable income and allowable deductions and the fair value calculations of stock-based compensation, goodwill, finite lived intangibles and the earn-out liability.
Reclassifications
Long term accounts receivable, net of allowance was previously reported as a component of current assets as accounts receivable, net of allowance, in the Company’s accompanying interim unaudited condensed consolidated balance sheets. Long term accounts receivable reflects Cases where the patient has obtained a letter of protection, (“LOP”). A LOP is a contract that provides that the medical providers will be paid from any proceeds received from settlement of litigation of the underlying cause of action with respect to the event that necessitated medical goods and services. Once the medical provider receives payment, then the medical provider pays the Company’s invoice which payment is generally greater than 365 day from date of service. The LOP provides medical providers with greater certainty of full payment. This reclassification had no effect on the previously reported total assets or net loss.
Segment Reporting
In accordance with Accounting Standards Codification (“ASC”) No. 280, “Segment Reporting,” the Company uses the management approach for determining its reportable segments. The management approach is based upon the way that management reviews performance and allocates resources. The Company’s Chief Executive Officer serves as the Company’s chief operating decision maker, and his management team reviews operating results on a consolidated basis for purposes of allocating resources and evaluating the financial performance of the Company. The Company has integrated the operations of both CPM and Maxim. Accordingly, the Company has determined that it has one operating segment and, therefore, one reporting segment.
Earnings (loss) Per Common Share
Earnings (loss) per common share, basic is calculated by dividing the net income/(loss) attributable to common stockholders by the weighted-average number of common stock, par value $0.01 (“Common Stock”), outstanding during the period, without consideration of Common Stock equivalents. Shares of restricted stock are included in the basic weighted-average number of Common Stock outstanding from the time they vest.
Diluted earnings (loss) per common share is computed by dividing net income/(loss) by the weighted-average number of Common Stock equivalents outstanding for the period determined using the treasury stock method. For the three and nine months ended September 30, 2020 and 2019, the Company excluded the effects of outstanding stock options, convertible notes and, to the extent in the money, restricted stock as their effects were antidilutive due to the Company’s operating loss during these periods. (See Note 9, “Stockholders’ Equity” for the terms and conditions of restricted stock).
F-6
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy:
Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets;
Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities; and
Level 3—Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities.
In connection with the CPM Acquisition in December 2017, the Company recorded an earn-out liability as part of the purchase consideration. The fair value of the earn-out liability is re-measured at each reporting period using Level 3 inputs with changes in fair value recorded in earnings. The earn-out payments are based on the financial performance of the Company between January 1, 2018, and December 31, 2034. The base amount of the earn-out ranges from $0.00 to $16,000,000 with an additional bonus payment of $10,000,000, subject to the Company meeting certain earnings thresholds as defined in the CPM Acquisition Agreement. The fair value of the earn-out liability was calculated using the Monte Carlo simulation, which was then applied to estimated earn-out payments. There was no change in the earn-out liability for the nine months ended September 30, 2020, and there were no significant changes in the Level 3 inputs from those utilized at December 31, 2019. The required earnings thresholds have not been met from inception of the agreements through September 30, 2020, and, as such, there have been no payments required for either the base or bonus earn-out tranches.
Financial Instruments
The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The recorded values of notes payable approximate their respective fair values based upon their effective interest rates.
Cash and Cash Equivalents
The Company considers highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents at September 30, 2020 and December 31, 2019. The Company’s cash is concentrated in large financial institutions that at times may exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any financial institution losses from inception through September 30, 2020. As of September 30, 2020 and December 31, 2019, there were deposits of $1,075,880 and $599,309, respectively, greater than federally insured limits.
Accounts Receivable and Allowances
Accounts receivable are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable and an allowance for contractual discount pricing. Credit is extended to customers based on an evaluation of their financial condition, industry reputation, and other factors considered by the Company’s management. The Company generally does not require collateral or other security interest to support accounts receivable. Based on trends and specific factors, the customer’s credit terms may be modified, including required payment upon delivery.
The Company performs regular on-going credit evaluations of its customers as deemed relevant. As events, trends, and circumstances warrant, the Company’s management estimates the amounts that are more likely than not to be uncollectible. These amounts are recognized as bad debt expense and are reflected within selling, general, administrative and other expenses on the Company’s accompanying interim unaudited condensed consolidated statements of operations.
When accounts are deemed uncollectible, they are often referred to the Company’s outside legal firm for litigation. Accounts deemed uncollectible are written-off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts. Accounts deemed uncollectible are removed from the Company’s accounts receivable portfolio, with a corresponding offset to the allowance for doubtful accounts receivable. The Company may record additional allowances for doubtful accounts based on known trends and
F-7
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
expectations to ensure the Company’s accounts receivable portfolio is recorded at net realizable value. Specific allowances are re-evaluated and adjusted as additional facts and information become available. Previously written-off accounts receivable subsequently collected are recognized as a reduction of bad debt expense when funds are received.
The Company’s management estimates its allowance for contractual discount pricing, by evaluating specific accounts where information indicates the customer is offered contractual pricing and discount allowances. In these arrangements, the Company’s management uses assumptions and judgement, based on the best available facts and circumstances to record a specific allowance for the amounts due from those customers. The allowance is offset by a corresponding reduction to revenue. These specific allowances are re-evaluated, analyzed, and adjusted as additional information becomes available to determine the total amount of the allowance. The Company may record additional allowances based on trends and expectations to ensure the Company’s accounts receivable portfolio is recorded at net realizable value.
Inventories
Inventories are stated at the lower of cost or net realizable value (first-in, first-out), which includes an allowance for slow-moving inventory, expired inventory, and inventory obsolescence. Inventories consist entirely of finished goods and include internal and external fixation products; upper and lower extremity plating and total joint reconstruction; soft tissue fixation and augmentation for sports medicine procedures; spinal implants for trauma, degenerative disc disease, and deformity indications (collectively, “Orthopedic Implants”) and osteo-biologics and regenerative tissue which include human allografts, substitute bone materials, tendons, and amniotic tissues and fluids (collectively, “Biologics”). The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit. In cases where the market values are less than the carrying value, a write-down is recognized equal to an amount by which the carrying value exceeds the market value of inventories.
Property and Equipment
Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets per the following table. Expenditures for additions and improvements are capitalized, while repairs and maintenance are expensed as incurred. The Company reviews long-lived assets for impairment annually or whenever changes in circumstances indicate that the carrying amount of an asset might not be recoverable.
|
Category |
|
Useful Life |
|
Computer equipment and software |
|
3 years |
|
Furniture and fixtures |
|
3 years |
|
Office equipment |
|
3 years |
|
Software |
|
3 years |
Upon the retirement or disposition of property and equipment, the related cost and accumulated depreciation is removed. A gain is recorded when consideration received is more than the disposed asset’s cost, net of depreciation, and a loss is recorded when consideration received is less than the disposed asset’s cost, net of depreciation.
Long-Lived Assets
The Company reviews other long-lived assets for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows, which is at the individual asset level or the asset group level. The undiscounted cash flows expected to be generated by the related assets are estimated over their useful life based on updated projections. If the evaluation indicates that the carrying amount of the assets may not be recoverable, any potential impairment is measured based upon the fair value of the related assets or asset group as determined by an appropriate market appraisal or other valuation technique. Assets classified as held for sale, if any, are recorded at the lower of carrying amount or fair value less costs to sell.
Goodwill and Other Intangible Assets
Goodwill is determined based on an acquisition purchase price in excess of the fair value of identified net assets acquired. Intangible assets with lives restricted by contractual, legal or other means are amortized over their useful lives.
F-8
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Goodwill is not amortized but is tested in the fourth quarter each year for impairment, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. The Company performs its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. If the carrying value of a reporting unit exceeds its fair value, an impairment charge is recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. As of September 30, 2020, the Company evaluated certain qualitative factors including, (i) macroeconomic factors resulting from the COVID-19 pandemic, (ii) the Company’s operating results and overall financial performance, (iii) the Company’s stock price, and (iv) specific cost-saving actions taken by the Company in response to the COVID-19 pandemic in concluding that the reported amount of goodwill was not more likely than not impaired.
Accounting Standards Update (“ASU”) 350-30-35-18 indicates that an intangible asset that is not subject to amortization shall be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. The Company’s 510(k) intangible asset has an indefinite life. The Company does not believe that triggering event has occurred as of September 30, 2020.
The Company’s intangible assets subject to amortization consist primarily of acquired non-compete agreements and customer relationships. Amortization expense is calculated using the straight-line method over the asset’s expected useful life.
Revenue Recognition
The Company’s revenues are generated from the sales of Orthopedic Implants and Biologics to support orthopedic surgeries. The Company obtains purchase orders from its customers for the sale of its products, which set forth the general terms and conditions including line item pricing and payment terms (generally due upon receipt). The Company recognizes revenue when its customers obtain control over the assets (generally when the title passes upon shipment or when a product is utilized in a surgery) and it is probable that the Company will collect substantially all the amounts due. Individual promised goods are the Company’s only performance obligation.
Due to the nature of its products, the Company’s product returns have been historically immaterial.
The Company includes shipping and handling fees in net revenues. Shipping and handling costs, associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold on the Company’s accompanying interim unaudited condensed consolidated statements of operations.
Revenue Differentiation
The Company measures sales volume based on medical procedures in which the Company’s products are sold and used (Cases). The Company considers Cases resulting from direct sales to medical facilities to be Retail Cases and Cases resulting from sales to third parties, such as non-medical facilities, distributors, or sub-distributors, to be wholesale cases (“Wholesale Cases”). Some of the Company’s sales for Wholesale Cases are on a consignment basis with a third party. When consigned, the revenue is not recorded until the device is implanted in a patient during surgery. In the Company’s industry, Retail Cases are typically sold at higher price points than Wholesale Cases, resulting in greater revenue and gross profit per Case.
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
|
September 30, 2020 |
|
|
September 30, 2019 |
|
|
September 30, 2020 |
|
|
September 30, 2019 |
|
||||
|
Category |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retail |
|
$ |
5,092,676 |
|
|
$ |
5,050,785 |
|
|
$ |
12,826,054 |
|
|
$ |
12,425,874 |
|
|
Wholesale |
|
|
645,986 |
|
|
|
665,559 |
|
|
|
1,559,777 |
|
|
|
3,137,054 |
|
|
Total |
|
$ |
5,738,662 |
|
|
$ |
5,716,344 |
|
|
$ |
14,385,831 |
|
|
$ |
15,562,928 |
|
Cost of Revenues
Cost of revenues consists of (i) cost of goods sold, (ii) freight and shipping costs for items sold to customers, (iii) cost of storage, (iv) investment in medical instruments, which are expensed when acquired, (v) inventory shrink, and (vi) an estimate for slow-moving and expired inventory, and inventory obsolescence.
F-9
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For employee stock-based awards, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model. Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based awards represent the Company's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. For non-employee stock-based awards, the Company calculates the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro-rata compensation expense is adjusted accordingly until such time the non-employee award is fully vested, at which time the total compensation recognized to date shall equal the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.
Recent Accounting Pronouncements
Accounting pronouncements issued or effective in 2020 by the Financial Accounting Standards Board (the “FASB”) did not have, or are not believed by the Company’s management to have, a material impact on the Company's present or future unaudited condensed consolidated financial statements.
Note 3. Property and Equipment
Property and equipment consisted of the following at September 30, 2020 and December 31, 2019:
|
|
|
September 30, 2020 |
|
|
December 31, 2019 |
|
||
|
Computer equipment and software |
|
$ |
45,411 |
|
|
$ |
51,303 |
|
|
Office equipment |
|
|
20,333 |
|
|
|
20,333 |
|
|
Property and equipment costs |
|
|
65,744 |
|
|
|
71,636 |
|
|
Less: accumulated depreciation |
|
|
(40,489 |
) |
|
|
(38,997 |
) |
|
Property and equipment, net |
|
$ |
25,255 |
|
|
$ |
32,639 |
|
Depreciation expense for the three months ended September 30, 2020 and 2019 was $8,116 and $5,241, respectively. Depreciation expense for the nine months ended September 30, 2020 and 2019 was $28,141 and $15,851, respectively.
Note 4. Goodwill and Intangible Assets
The following table summarizes the Company’s goodwill and other intangible assets:
|
|
|
September 30, 2020 |
|
|
December 31, 2019 |
|
|
Amortization period (years) |
||
|
Intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
Non-compete agreements |
|
$ |
- |
|
|
$ |
61,766 |
|
|
2 |
|
510(k) product technology |
|
|
704,380 |
|
|
|
704,380 |
|
|
Indefinite |
|
Customer relationships |
|
|
555,819 |
|
|
|
555,819 |
|
|
11 |
|
Total intangible assets |
|
|
1,260,199 |
|
|
|
1,321,965 |
|
|
|
|
Less: accumulated amortization |
|
|
(109,486 |
) |
|
|
(115,345 |
) |
|
|
|
Intangible assets, net |
|
|
1,150,713 |
|
|
|
1,206,620 |
|
|
|
|
Goodwill |
|
$ |
1,972,886 |
|
|
$ |
1,972,886 |
|
|
Indefinite |
F-10
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Amortization expense for the three months ended September 30, 2020 and 2019 was $15,197 and $20,355, respectively. Amortization expense for the nine months ended September 30, 2020 and 2019, was $55,906 and $61,065, respectively.
The Company’s intangible assets subject to amortization consist primarily of acquired non-compete agreements, and customer relationships.
Note 5. Senior Secured Revolving Credit Facility
Effective December 29, 2017, the Company became party to its RLOC with Amegy Bank. The RLOC contains customary representation, warranties, covenants and events of default and is collateralized by substantially all of the Company’s assets. The Company’s Chairman of the Board of Directors (“Board”) and President initially personally guaranteed fifty percent (50%) of the outstanding RLOC amount.
On September 21, 2018, the Company executed the First Amendment to the RLOC with Amegy Bank (the “First Amendment”). The First Amendment (i) waived the Company’s events of default under the RLOC through the fiscal quarter ended September 30, 2018, and (ii) added a covenant that the Company achieve quarterly net income of $700,000 or more for the fiscal quarter ending on September 30, 2018.
On November 19, 2018, the Company executed the Second Amendment to the RLOC with Amegy Bank (the “Second Amendment”). The Second Amendment (i) waived the Company’s events of default under the RLOC, (ii) reduced the aggregate limit of the RLOC to $4,000,000, (iii) extended the maturity date to November 4, 2019, (iv) revised the variable interest rate to the one-month LIBOR rate plus four percent (4.00%) per annum, and (v) amended the financial covenants to state that the Company will not permit the Fixed Charge Coverage Ratio of any calendar quarter end from and after the quarter ending June 30, 2019, to be less than 1.25 to 1.00; EBITDA to be less than $700,000 for the fiscal quarter ending December 31, 2018, and $100,000 for the fiscal quarter ending March 31, 2019; and modified the event of default related to consecutive quarterly losses to be applicable from and after the quarter ending June 30, 2019.
F-11
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
On May 9, 2019, the Company executed the Third Amendment to the RLOC with Amegy Bank (the “Third Amendment”). Pursuant to the Third Amendment Amegy Bank (i) waived the Company’s events of default under the RLOC, (ii) reduced the aggregate limit of the RLOC to $3,500,000, (iii) reduced the limit of credit card exposure to $500,000, (iv) reduced borrowing base component of inventory to 30%, (v) amended the financial covenants to state that the Company will not permit EBITDA to be less than $100,000 for the fiscal quarter ending June 30, 2019 and $500,000 for the fiscal quarter ending September 30, 2019 and (vi) rescinded the Loan Sweep Feature, requiring the Company to give notice of each requested loan by delivery of Advance Request to Amegy Bank.
On December 18, 2019, the Company executed the Fourth Amendment to the RLOC with Amegy Bank (the “Fourth Amendment”). Pursuant to the Fourth Amendment, Amegy Bank (i) waived the Company’s events of default under the RLOC, (ii) reduced the aggregate limit of the RLOC to $2,750,000, (iii) reduced and limited the annual salary of the Company’s Chairman of the Board and President, Mark W. Brooks (“Mr. Brooks”), to not exceed $550,000, (iv) amended the financial covenants to state that the Company will not permit EBITDA to be less than $600,000 for the fiscal quarter ending December 31, 2019 and $125,000 for the fiscal quarter ending March 31, 2020, (v) extended the termination date of the RLOC to May 4, 2020 and (vi) provided for our Chairman of the Board and President to personally guarantee one hundred percent (100%) of the outstanding RLOC amount.
On May 21, 2020, the Company executed the Fifth Amendment to the RLOC with Amegy Bank (“the Fifth Amendment”). Pursuant to the Fifth Amendment, Amegy Bank (i) waived the Company’s events of default under the RLOC, (ii) amended the financial covenants to state that the Company will not permit EBITDA to be less than $25,000 for the six months ended September 30, 2020, and (iii) extended the termination date of the RLOC until November 4, 2020.
In conjunction with executing the Fifth Amendment to the RLOC, the Company obtained an additional $200,000 in capital in the form of subordinated debt from affiliates of Messrs. Brooks and Reeg. Specifically, on May 6, 2020, the Company borrowed $180,000 from NC 143 Family Holdings, LP (“NC 143”), a limited partnership controlled by Mr. Brooks, the Company’s President and Chairman of the Board, and $20,000 from Reeg Medical Industries, Inc. (“RMI”), a company owned and controlled by Christopher C. Reeg (“Mr. Reeg”), the Company’s Chief Executive Officer and Secretary, in exchange for two promissory notes which are unsecured and bear interest at 0.25% per annum until May 6, 2022, the maturity date, and 10.0% per annum after the maturity date, if not paid in full. Principal and interest are due and payable on the maturity date, provided, however, any payment of principal and interest on the loans is subordinated to payment of all indebtedness under the RLOC.
Pursuant to the Fifth Amendment to the RLOC, the Company was in compliance with the covenants of its RLOC with Amegy Bank for the six months ended September 30, 2020.
The outstanding balance of the RLOC was $1,038,352 and $1,752,501 at September 30, 2020 and December 31, 2019, respectively. Interest expense incurred on the RLOC was $11,354 and $28,095 for the three months ended September 30, 2020 and 2019, respectively, and is reflected in interest expense on the Company’s accompanying unaudited condensed consolidated statements of operations. Interest expense incurred on the RLOC was $50,987 and $68,168 for the nine months ended September 30, 2020 and 2019, respectively. Accrued interest on the RLOC at September 30, 2020 and December 31, 2019 was $3,236 and $4,437, respectively, and is reflected in accrued expenses on the Company’s accompanying interim unaudited condensed consolidated balance sheets. At September 30, 2020, the effective interest rate was 4.76%.
Note 6. Notes Payable – Related Parties
During July 2016 through October 2016, the Company obtained three working capital loans from NC 143 and RMI in the form of convertible promissory notes (“Notes”) in the aggregate amount of $150,000 bearing ten percent (10%) interest per annum until December 31, 2016 (“Maturity Date”), and eighteen percent (18%) interest per annum for periods subsequent to the Maturity Date. The Notes remain outstanding and principal and interest are due and payable upon demand of the payee and at the holder’s sole discretion. The Notes’ holders have the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s Common Stock at a conversion price of $0.08 per share. On May 6, 2020, the Company borrowed $180,000 from NC 143 and $20,000 from RMI, in exchange for two promissory notes which are unsecured and bear interest at 0.25% per annum until May 6, 2022, the maturity date, and 10.0% per annum after the maturity date, if not paid in full. Principal and interest are due and payable on the maturity date, provided, however, any payment of principal and interest on the loans is subordinated to payment of all indebtedness under the RLOC.
During the three months ended September 30, 2020 and 2019, interest expense of $6,930 and $6,805, respectively, is reflected in interest expense on the Company’s accompanying unaudited condensed consolidated statements of operations. During the nine months ended September 30, 2020 and 2019, interest expense of $20,477 and $20,195, respectively, is reflected in interest expense on the Company’s accompanying unaudited condensed consolidated statements of operations. As of September 30, 2020, and December 31,
F-12
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
2019, accrued interest was $106,572 and $86,096, respectively, which is reflected in accrued expenses on the Company’s accompanying unaudited condensed consolidated balance sheets.
Note 7 – Paycheck Protection Program Loan
On April 11, 2020, the Company received approval from the U.S. Small Business Administration (“SBA”) to fund the Company’s request for a loan under the Paycheck Protection Program (“PPP Loan”) created as part of the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the SBA. In connection with the PPP Loan, the Company has entered into a promissory note in the principal amount of $361,400. In accordance with the requirements of the CARES Act, the Company intends to use the proceeds from the PPP Loan primarily for payroll costs. The PPP Loan is scheduled to mature on April 11, 2022, has a 1.00% interest rate, and is subject to the terms and conditions applicable to all loans made pursuant to the Paycheck Protection Program as administered by the SBA under the CARES Act. The PPP Loan is reflected in short term liabilities in the Company’s accompanying interim unaudited condensed consolidated balance sheets as the Company expects the PPP Loan will be forgiven during 2020.
As of September 30, 2020, the Company incurred approximately $1,810 in accrued interest related to the PPP Loan, which is reflected in accrued expenses on the Company’s accompanying interim unaudited condensed consolidated balance sheets. For the three months and nine months ended September 30, 2020, the Company incurred approximately $907 and $1,810, respectively, in interest expense related to the PPP Loan, which is reflected in interest expense on the Company’s statements of operations. The Company did not incur interest expense related to the PPP Loan for the three and nine months ended September 30, 2019.
Note 8 – Economic Injury Disaster Loan
On May 12, 2020, the Company executed the standard loan documents required for securing a loan from the SBA under its Economic Injury Disaster Loan assistance program (the “EIDL Loan”) in light of the impact of the COVID-19 pandemic on the Company’s business. Pursuant to the Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan was $150,000, with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due monthly beginning May 12, 2021 (twelve months from the date of the SBA Loan Agreement) in the amount of $731. The balance of principal and interest is payable thirty years from the date of the SBA Loan Agreement. The EDIL Loan is reflected in long term liabilities in the Company’s accompanying interim unaudited condensed consolidated balance sheets. In connection therewith, the Company received a $10,000 advance, which does not have to be repaid and is reflected as an offset in Selling, General, Administrative and Other Expenses in the Company’s accompanying interim unaudited condensed consolidated statements of operations.
As of September 30, 2020, the Company incurred approximately $2,359 in accrued interest related to the EIDL Loan, which is reflected in accrued expenses on the Company’s accompanying interim unaudited condensed consolidated balance sheets. The Company did not incur accrued interest expense on the EIDL Loan as of September 30, 2019. For the three months and nine months ended September 30, 2020, the Company incurred approximately $1,419 and $2,359 in interest expense related to the EIDL Loan, which is reflected in interest expense on the Company’s statements of operations. The Company did not incur interest expense related to the EIDL Loan for the three and nine months ended September 30, 2019.
Note 9. Stockholders’ Equity
Stock-Based Compensation
The 2018 Amended and Restated Equity Incentive Plan of Fuse Medical, Inc. (“2018 Equity Plan”) is the Company’s stock-based compensation plan, which the Company’s Board adopted on April 5, 2017, and subsequently amended and restated on December 13, 2018. The 2018 Equity Plan provides for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards, and restricted stock awards to employees, directors, consultants, and advisors. Awards granted pursuant to the 2018 Equity Plan are subject to a vesting schedule set forth in individual agreements.
The Company’s management estimates the fair value of stock-based compensation utilizing the Black-Scholes option pricing model. Black-Scholes option pricing is calculated using several variables, including the expected option term, expected volatility of the Company’s stock price over the expected option term, expected risk-free interest rate over the expected option term, expected dividend yield rate over the expected option term, and an estimate of expected forfeiture rates. The Company’s management believes this valuation methodology is appropriate for estimating the fair value of stock options granted to employees and directors, which are
F-13
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
subject to ASC Topic 718 requirements. The Company’s management estimates of fair value may not be reflective of actual future values or amounts ultimately realized by recipients of these grants. The Company recognizes compensation on a straight-line basis over the requisite service period for each award.
The Company’s management utilizes the simplified method to estimate the expected life for stock options granted to employees, as the Company does not have sufficient historical data regarding stock option exercises. The risk-free interest rate is based on the U.S. Treasury yields with terms equivalent to the expected life of the related option at the time of the grant. Dividend yield is based on historical trends. While the Company’s management believes these estimates are reasonable, the compensation expense recorded would increase if the expected life was increased, a higher expected volatility was used, or if the expected dividend yield increased.
The Company made an accounting policy election to account for forfeitures when they occur, versus estimating the number of awards that are expected to vest, in accordance with ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting.”
Non-Qualified Stock Option Awards
For the three and nine months ended September 30, 2019 the Board granted 150,000 and 1,350,000 Non-qualified Stock Option (“NQSO”) to the Company’s product advisory board members, certain key employees and marketing representatives. For the three and nine months ended September 30, 2020, the Board did not grant any NQSOs. For the three months ended September 30, 2020 and September 30, 2019 the Company amortized $101,817 and recognized a benefit of $11,583 relating to the vesting of stock options which is included in selling, general, administrative, and other expenses on the Company’s accompanying interim unaudited condensed consolidated statement of operations. For the nine months ended September 30, 2020 and September 30, 2019 the Company amortized $428,915 and $487,524 relating to the vesting of stock options which is included in selling, general, administrative, and other expenses on the Company’s accompanying interim unaudited condensed consolidated statements of operations. The Company will recognize $439,434 as an expense in future periods as the stock options vest. The Company recognizes stock compensation expense on a straight-line basis over the requisite service period for each award, which are subject to a vesting schedule as set forth in individual agreements.
A summary of the Company’s stock option activity for the nine months ended September 30, 2020, is presented below:
|
|
|
No. of Shares |
|
|
Weighted Average Exercise Price |
|
|
Weighted Average Remaining Contractual Term |
|
|
Aggregate Intrinsic Value |
|
||||
|
Balance outstanding at December 31, 2019 |
|
|
3,948,333 |
|
|
$ |
0.61 |
|
|
|
6.08 |
|
|
$ |
157,000 |
|
|
Granted |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Exercised |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Forfeited |
|
|
(703,333 |
) |
|
|
0.74 |
|
|
|
- |
|
|
|
- |
|
|
Expired |
|
|
(600,000 |
) |
|
|
0.26 |
|
|
|
- |
|
|
|
- |
|
|
Balance outstanding at September 30, 2020 |
|
|
2,645,000 |
|
|
$ |
0.65 |
|
|
|
6.22 |
|
|
$ |
- |
|
|
Exercisable at September 30, 2020 |
|
|
1,663,333 |
|
|
$ |
0.58 |
|
|
|
5.05 |
|
|
$ |
- |
|
Restricted Common Stock
The non-vested restricted stock awards (“RSA”s), as of September 30, 2020, were granted to the Company’s Board members as compensation. These awards vest only upon: (i) the occurrence of one of the Accelerating Events: (a) a Change in Control (as defined in RSA Agreement); or (b) listing of the Company’s Common Stock on either NYSE or NASDAQ Stock Market; and (ii) the director’s delivery to the Company a Notice of Acceleration of Vesting (as defined in RSA Agreement), within the Acceleration Notice Period (as defined in RSA Agreement).
As of September 30, 2020, and 2019, it was not probable that the performance conditions on the outstanding RSAs would be met therefore, no expense has been recorded for these awards for the three and nine months ended September 30, 2020 and 2019.
There were no RSA’s that were granted, exercised, or forfeited during the nine months ended September 30, 2020.
F-14
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
|
Number of Shares |
|
|
Fair Value |
|
|
Weighted Average Grant Date Fair Value |
|
||||
|
Non-vested, December 31, 2019 |
|
2,902,892 |
|
|
$ |
1,382,800 |
|
|
$ |
0.48 |
|
|
Granted |
|
- |
|
|
|
- |
|
|
|
- |
|
|
Vested |
|
- |
|
|
|
- |
|
|
|
- |
|
|
Forfeited |
|
- |
|
|
|
- |
|
|
|
- |
|
|
Non-vested, September 30, 2020 |
|
2,902,892 |
|
|
$ |
1,382,800 |
|
|
$ |
0.48 |
|
Note 10. Income Taxes
The Company is subject to U.S. federal income taxes, in addition to state and local income taxes.
The components of income tax expense (benefit) are as follows:
|
|
|
For the Nine Months Ended September 30, 2020 |
|
|
For the Nine Months Ended September 30, 2019 |
|
||
|
Current: |
|
|
|
|
|
|
|
|
|
Federal |
|
$ |
- |
|
|
$ |
- |
|
|
State |
|
|
11,341 |
|
|
|
10,589 |
|
|
|
|
|
11,341 |
|
|
|
10,589 |
|
|
Deferred: |
|
|
|
|
|
|
|
|
|
Federal |
|
|
- |
|
|
|
760,993 |
|
|
State |
|
|
- |
|
|
|
- |
|
|
|
|
|
- |
|
|
|
760,993 |
|
|
Total income tax expense |
|
$ |
11,341 |
|
|
$ |
771,582 |
|
Significant components of the Company's deferred income tax assets and liabilities are as follows:
|
|
|
September 30, 2020 |
|
|
September 30, 2019 |
|
||
|
|
|
|
|
|
|
|
|
|
|
Net operating loss carryover |
|
$ |
843,582 |
|
|
$ |
191,319 |
|
|
Accounts receivable |
|
|
168,344 |
|
|
|
366,996 |
|
|
Stock based compensation |
|
|
454,678 |
|
|
|
335,173 |
|
|
Inventory |
|
|
610,215 |
|
|
|
893,231 |
|
|
Other |
|
|
7,341 |
|
|
|
28,129 |
|
|
Total deferred tax assets |
|
|
2,084,160 |
|
|
|
1,814,848 |
|
|
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities: |
|
|
|
|
|
|
|
|
|
Intangibles |
|
|
(208,703 |
) |
|
|
(222,029 |
) |
|
Property and equipment |
|
|
(4,214 |
) |
|
|
(4,950 |
) |
|
Total deferred tax liabilities |
|
|
(212,917 |
) |
|
|
(226,979 |
) |
|
|
|
|
|
|
|
|
|
|
|
Deferred tax assets, net |
|
$ |
1,871,243 |
|
|
$ |
1,587,869 |
|
|
|
|
|
|
|
|
|
|
|
|
Valuation allowance: |
|
|
|
|
|
|
|
|
|
Beginning of year |
|
|
(1,529,584 |
) |
|
|
- |
|
|
Increase during the year |
|
|
(341,659 |
) |
|
|
(1,587,869 |
) |
|
Ending balance |
|
|
(1,871,243 |
) |
|
|
(1,587,869 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net deferred tax asset |
|
$ |
- |
|
|
$ |
- |
|
F-15
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
|
At September 30, 2020, the Company estimated it had approximately $4,017,055 of net operating loss carryforwards of which $899,331 will expire during 2020 through 2037. The Company believes its tax positions are more likely than not of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions. As of September 30, 2020, the Company's tax years 2016 through 2018 remain open for Internal Revenue Service ("IRS") audit. The Company has not received a notice of audit from the IRS for any of the open tax years.
On March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The Company is currently evaluating the impact of the CARES Act, but at present does not expect that the NOL carryback provision of the CARES Act to result in a material impact to the Company. O
|
A reconciliation of income tax computed at the U.S. statutory rate to the effective income tax rate is as follows:
|
|
|
Nine Months Ended |
|
|||
|
|
|
September 30, 2020 |
|
|
September 30, 2019 |
|
|
Expected U.S. federal incomes as statutory rate |
|
21.0% |
|
|
21.0% |
|
|
Change in deferred tax asset valuation allowance |
|
-21.1% |
|
|
0.0% |
|
|
State and local income taxes, net of federal benefit |
|
-0.6% |
|
|
-1.3% |
|
|
Permanent differences |
|
0.0% |
|
|
-0.5% |
|
|
Other |
|
0.0% |
|
|
0.0% |
|
|
Effective tax rate |
|
-0.7% |
|
|
19.2% |
|
The Company’s effective income tax rates for the nine months ended September 30, 2020 and 2019 were (.7%) and 19.2%, respectively. The decrease from the prior period was driven by the valuation allowance allocated to the deferred tax asset for the current period.
Note 11. Concentrations
Concentration of Revenues, Accounts Receivable and Suppliers
For the nine months ended September 30, 2020 and 2019, the following significant customers had an individual percentage of total revenues equaling ten percent (10%) or greater:
|
|
For the Nine Months Ended |
|
|||||
|
|
September 30, 2020 |
|
|
September 30, 2019 |
|
||
|
Customer 1 |
|
13.70 |
% |
|
|
4.50 |
% |
|
Totals |
|
13.70 |
% |
|
|
4.50 |
% |
At September 30, 2020 and December 31, 2019, the following significant customers had a concentration of accounts receivable representing ten percent (10%) or greater of accounts receivable:
|
|
September 30, 2020 |
|
|
December 31, 2019 |
|
||
|
Customer 1 - related party |
|
12.49 |
% |
|
|
9.47 |
% |
|
Totals |
|
12.49 |
% |
|
|
9.47 |
% |
F-16
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the nine months ended September 30, 2020 and 2019, the following significant suppliers represented ten percent (10%) or greater of goods purchased:
|
|
For the Nine Months Ended |
|
|||||
|
|
September 30, 2020 |
|
|
September 30, 2019 |
|
||
|
Supplier 1 |
|
24.70 |
% |
|
|
21.90 |
% |
|
Supplier 2 - related party |
|
7.50 |
% |
|
|
10.30 |
% |
|
Totals |
|
32.20 |
% |
|
|
32.20 |
% |
Note 12. Related Party Transactions
Lease with 1565 North Central Expressway, LP
For its principal executive office, the Company leases approximately 11,500 square feet of space at 1565 North Central Expressway, Suite 220, Richardson, Texas 75080 from 1565 North Central Expressway, LP (“NCE, LP”), a real estate investment company that is owned and controlled by Mr. Brooks. The Company’s lease arrangement includes (i) the lease acquired pursuant to the CPM Acquisition effective January 1, 2013, and (ii) a lease effective July 14, 2017, entered into to support the Company’s relocation of its Fort Worth, Texas corporate offices to CPM’s executive offices. Both leases terminated December 31, 2017, with month-to-month renewals thereafter.
For the nine months ended September 30, 2020 and 2019, the Company paid approximately $126,000 and $126,000, respectively, in rent expense, which is reflected in selling, general, administrative, and other expenses in the Company’s accompanying interim unaudited condensed consolidated statements of operations.
AmBio Contract
The Company engaged AmBio Staffing, LLC (“AmBio”), a Texas licensed Professional Employment Organization, to provide payroll processing, employee benefit administration, and related human capital services effective January 1, 2017. Mr. Brooks owns and controls AmBio. As of September 30, 2020, AmBio operations support approximately 44 full time equivalents (“FTE”). Of those 44 FTEs, 37 FTEs directly support the Company, 6 FTEs support the operations of other companies, and one FTE is shared between the Company and other companies.
As of September 30, 2020 and December 31, 2019, the Company owed amounts to AmBio of approximately $138,773 and $170,000, respectively, which are reflected in accounts payable on the Company’s unaudited condensed consolidated balance sheets. For the nine months ended September 30, 2020 and September 30, 2019, the Company paid approximately $131,851 and $154,000, respectively, to AmBio in administrative fees, which are reflected in selling, general, administrative, and other expenses in the Company’s accompanying unaudited condensed consolidated statements of operations.
Operations
Historically, the Company conducts various related-party transactions with entities that are owned by or affiliated with Mr. Brooks and Mr. Reeg. These transactions are based on wholesale contractual agreements that the Company’s management believes are on terms and conditions substantially similar to other third-party contractual agreements. As described more fully below, these transactions include: selling and purchasing of inventory on a wholesale basis, commissions earned and paid and shared-service fee arrangements.
MedUSA Group, LLC
MedUSA Group, LLC (“MedUSA”) is a sub-distributor owned and controlled by Mr. Brooks and Mr. Reeg.
During the nine months ended September 30, 2020 and 2019, the Company:
|
|
• |
sold Orthopedic Implants and Biologics products to MedUSA in the amounts of approximately $29,822 and $751,000, respectively, which are reflected in net revenues in the Company’s accompanying interim unaudited condensed consolidated statements of operations; and |
F-17
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
As of September 30, 2020 and December 31, 2019, the Company had approximately $659,767 and $598,000, respectively, of unpaid commission costs due to MedUSA, which are reflected in accrued liabilities in the Company’s accompanying condensed consolidated balance sheets.
As of September 30, 2020 and December 31, 2019, the Company had outstanding balances due from MedUSA of approximately $501,543 and $555,000, respectively. These amounts are reflected in accounts receivable, net of allowance in the Company’s accompanying condensed consolidated balance sheets.
Texas Overlord, LLC
Texas Overlord, LLC (“Overlord”) is an investment holding-company owned and controlled by Mr. Brooks.
During the nine months ended September 30, 2020 and 2019, the Company:
|
|
• |
purchased approximately $0 and $25,000, respectively, in Orthopedic Implants and medical instruments, and Biologics from Overlord, which are reflected within inventories on the Company’s accompanying interim unaudited condensed consolidated balance sheets; and |
|
|
• |
incurred approximately $135,000 and $90,000, respectively, in commission costs, which are reflected in commissions in the Company’s accompanying interim unaudited condensed consolidated statements of operations. |
As of September 30, 2020 and December 31, 2019, the Company had approximately $15,000 and $15,000 of unpaid commissions costs owed to Overlord, which are reflected in accrued liabilities in the Company’s accompanying condensed consolidated balance sheets.
As of September 30, 2020 and December 31, 2019, the Company had no outstanding balances due to or from Overlord.
NBMJ, Inc.
NBMJ, Inc. d/b/a Incare Technology (“NBMJ”) is a durable medical equipment, wound care, and surgical supplies distributor owned and controlled by Mr. Brooks.
During the nine months ended September 30, 2020 and 2019, the Company sold Biologics products to NBMJ in the amounts of approximately $13,770, and $412,000, respectively, which are reflected in net revenues in the Company’s accompanying interim unaudited condensed consolidated statements of operations.
As of September 30, 2020 and December 31, 2019, the Company had $1,420 and zero in outstanding balances due from NBMJ.
Payment terms per the stocking and distribution agreement with NBMJ are 30 days from receipt of invoice.
Bass Bone and Spine Specialists
Bass Bone & Spine Specialists (“Bass”) operates as a sub-distributor of surgical implants and is owned and controlled by Mr. Brooks.
During the nine months ended September 30, 2020 and 2019, the Company:
|
|
• |
sold Orthopedic Implants and Biologics products to Bass in the amounts of approximately $55,897 and $106,000, respectively, which are reflected in net revenues in the Company’s accompanying interim unaudited condensed consolidated statements of operations; and |
|
|
• |
incurred approximately $16,885 and $16,000, respectively, in commission costs to Bass, which is reflected in commissions in the Company’s accompanying interim unaudited condensed consolidated statements of operations. |
As of September 30, 2020 and December 31, 2019, the Company had outstanding balances due from Bass of approximately $9,975 and $7,000, respectively. These amounts are reflected in accounts receivable, net of allowance, in the Company’s accompanying condensed consolidated balance sheets.
Payment terms per the stocking and distribution agreement with Bass are 30 days from receipt of invoice.
Sintu, LLC
Sintu, LLC (“Sintu”) operates as a sub-distributor of surgical implants and is owned and controlled by Mr. Brooks.
F-18
FUSE MEDICAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
During the nine months ended September 30, 2020 and 2019, the Company incurred approximately $482,308 and $269,000, respectively, in commission costs to Sintu, which are reflected in commissions on the Company’s accompanying interim unaudited condensed consolidated statements of operations.
Tiger Orthopedics, LLC
Tiger Orthopedics, LLC (“Tiger”) operates as a sub-distributor of surgical implants and is owned and controlled by Mr. Brooks.
During the nine months ended September 30, 2020 and September 30, 2019, the Company sold Orthopedic Implants and Biologics products to Tiger in the amounts of approximately $39,922 and $189,000, respectively, which are reflected in net revenues in the Company’s accompanying interim unaudited condensed consolidated statements of operations.
As of September 30, 2020 and December 31, 2019, the Company had outstanding balances due from Tiger of approximately $836 and $30,000, respectively. These amounts are reflected in accounts receivable, net of allowance, in the Company’s accompanying condensed consolidated balance sheets.
Payment terms per the stocking and distribution agreement with Tiger are 30 days from receipt of invoice.
Modal Manufacturing, LLC
Modal Manufacturing, LLC (“Modal”) is a manufacturer of medical devices owned and controlled by Mr. Brooks.
During the nine months ended September 30, 2020 and 2019, the Company purchased approximately $355,274 and $624,000, respectively, in Orthopedic Implants and medical instruments from Modal, which are reflected within inventories, net of allowance in the Company’s accompanying interim unaudited condensed consolidated balance sheets.
As of September 30, 2020 and December 31, 2019, the Company had outstanding balances owed to Modal of approximately $314,574 and $0, respectively. These amounts are reflected in accounts payable in the Company’s accompanying condensed consolidated balance sheets.
As of September 30, 2020 and December 31, 2019, the Company had outstanding balances due from Modal of approximately $0 and $40,700, respectively. These are reflected in accounts receivable, net of allowance, in the Company’s accompanying condensed consolidated balance sheets.
Payment terms per the stocking and distribution agreement with Modal are 30 days from receipt of invoice.
Note 13. Subsequent Events
On November 12, 2020, the Company and Amegy Bank executed the Sixth Amendment to the RLOC, extended the termination date of the RLOC until May 4, 2021. (See Note 5, “Revolving Line of Credit”).
The Company’s Management concluded there are no other material events or transactions for potential recognition or disclosure.
F-19
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Explanatory Note
As used in this report on Form 10-Q, “we”, “us”, “our”, and the “Company” refer to Fuse Medical, Inc, a Delaware corporation, and its consolidated subsidiaries.
This discussion and analysis should be read in conjunction with our interim unaudited condensed consolidated financial statements and the related notes included in this report for the periods presented (our “Financial Statements”), our audited consolidated financial statements and the related notes thereto and the Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2019 Annual Report.
Overview
We are a manufacturer and national distributor of medical devices. We provide a broad portfolio of orthopedic implants including:
|
|
• |
Foot and Ankle: internal and external fixation products; |
|
|
• |
Orthopedics: upper and lower extremity plating and total joint reconstruction implants; |
|
|
• |
Sports Medicine: soft tissue fixation and augmentation for sports medicine procedures; |
|
|
• |
Spine: full spinal implants for trauma, degenerative disc disease, and deformity indications (collectively, we refer to these bulleted products as “Orthopedic Implants”). |
We also provide a wide array of osteo-biologics and regenerative tissues, which include human allografts, substitute bone materials, tendons, and amniotic tissues and fluids, which we refer to as (“Biologics”).
All of our medical devices are approved by the U.S. Food and Drug Administration (“FDA”) for sale in the United States, and all of our Biologics suppliers are licensed tissue banks accredited by the American Association of Tissue Banks. Additionally, we are an FDA-registered medical device specification developer and repackager/relabeler, and manufacturer of record (a “Manufacturer”). We are seeking to grow our manufacturing operations, both by internal product development and by acquiring existing FDA approved devices.
Impact of COVID-19
Impact to Fuse
The novel coronavirus SARS CoV-2 (“COVID-19”) global pandemic presents significant risks to our business plan. During our first quarter 2020 and as a response to COVID-19, the Governor of Texas declared a state of disaster and issued an executive order requiring hospitals to defer all elective surgeries. The order was effective March 19, 2020 through April 22, 2020.
On April 17, 2020, the Governor of Texas issued an additional executive order permitting hospital facilities to begin elective surgeries effective April 22, 2020 with certain restrictions, including maintaining a percentage of available beds for potential COVID-19 related patients. The disaster declaration in Texas and similar declarations other governmental jurisdictions, specifically the temporary deferral of all elective surgeries, adversely impacted our results of operations for the second quarter 2020, in particular, the periods prior to April 22, 2020.
Our products support patient conditions which are degenerative in nature. While most of our Cases are currently considered elective, they are typically necessary for a patient to restore mobility, reduce pain and increase quality of life. We continue to believe our annual revenues for 2020 will fall within a range of 4% to 6% lower compared to 2019. Our revenues during our second quarter were significantly lower than the three months ended June 30, 2019 due to the restrictions on elective surgeries in place prior to April 22, 2020. For the three months ended September 30, 2020 our revenues exceeded the prior year quarter by $22,318. We anticipate this steady increase in revenues to continue throughout the fourth quarter of the year.
3
Seasonality
We are subject to seasonal fluctuations in sales, which cause fluctuations in quarterly results of operations. Because of the seasonality of our business, results for any quarter are not necessarily indicative of results that may be achieved in other quarters or for a full fiscal year.
Historically, we have experienced greater revenue and greater sales volume, as a percentage of revenue, during the last two calendar quarters of our fiscal year compared to the first two calendar quarters of the year. We believe this revenue trend is primarily due to the increase in elective surgeries during the last two quarters of the calendar year, which are partially satisfied by patient annual healthcare deductibles being met in those two quarters. We use this seasonality trend to assist us in enterprise-wide resource planning, such as purchasing and product inventory logistics.
Subsequent to the government-imposed shelter-in-place mandates and prohibitions on elective surgeries, revenues for the third quarter of 2020 were higher than our historical seasonality trends due to surgeries forgone in the second quarter of 2020 due to elective surgery restrictions being performed in the third quarter.
Retail and Wholesale Cases
We believe our comprehensive selection of Orthopedic Implants and Biologics products is essential to our ability to acquire new customers and increase sales volume, revenues, and profitability. We continue to review and evaluate our product lines, ensuring we maintain a high-quality and cost-effective selection of Orthopedic Implants and Biologics.
Retail. Under our retail distribution model, (“Retail Model”), we sell directly to our end customers, which consist of hospitals and medical facilities, utilizing (i) our full-time sales representatives whom we employ or engage as independent contractors and (ii) independent sales representatives who work on a non-exclusive basis. In both instances, we pay the sales representative a commission with respect to sales made by the representative. We refer to sales through our Retail Model as Retail Cases (which are herein referred to as “Retail Cases”).
Wholesale. Under our wholesale distribution model, (“Wholesale Model”), we sell our products directly to independent distributors rather than to hospitals and medical facilities who are the ultimate end customer. We do not pay or receive commissions from any sales by the independent distributor to the end customer. We refer to our sales through our Wholesale Model as Wholesale Cases, (which are herein referred to as “Wholesale Cases”).
Retail Cases in our industry command higher revenue price points than Wholesale Cases. Because Retail Cases involve direct sales to our end customers, we receive a higher profit margin due to the absence of any third party in the sales process, before we pay any potential commissions to a full time or independent sales representative. As a result, Retail Cases generally generate substantially more gross profit than Wholesale Case transactions.
In the quarter ended September 30, 2020, our average revenue per Retail Case increased by approximately 5%, and our average revenue per Wholesale Case increased by approximately 102% compared to the quarter ended September 30, 2019.
Wholesale Cases in our industry command lower revenue price-points than Retail Cases. Because Wholesale Cases involve sales to third parties who in turn sell our products to end customers, our profit margins are reduced for these Cases. Thus, our Wholesale Cases generate substantially lower gross profit than our Retail Cases, but are not subject to additional overhead support costs, such as case coverage and commissions. Our Wholesale Case business is highly dependent on minimum volume sales levels to achieve appropriate profitability.
During the nine months ended September 30, 2020, our average revenue per Retail Case increased by approximately 12%, and our average revenue per Wholesale Case increased by approximately 59% compared to the nine months ended September 30, 2019.
Pricing Pressure
Pricing pressure has increased in our industry due to (i) continuous consolidation among healthcare providers, (ii) trends toward managed care, (iii) increased government oversight of healthcare costs, and (iv) new laws and regulations that address healthcare reimbursement and pricing. Pricing pressure, reductions in reimbursement levels or coverage, or other cost containment measures can significantly impact our business, operating results and financial condition.
We employ strategies to maximize revenue per Case. For the nine months ended September 30, 2020 and 2019, our average revenues per Case were $5,406 and $4,033, respectively. The approximate 34% increase in average revenue per Case was primarily due to (a)(i) a shift to focus on Retail Cases, and (ii) an increase in revenue derived from commission agreements, offset, in part, by (b) continued pricing pressures, as described above.
4
We continue to experience gross profit improvements primarily based on revenues derived from our manufactured branded products and reduced distribution overhead costs.
Critical Accounting Policies
The preparation of our Financial Statements and the related disclosures in conformity with GAAP, requires our management to make judgments, assumptions, and estimates that affect the amounts of revenue, expenses, income, assets, and liabilities, reported in our Financial Statements and accompanying notes. Understanding our accounting policies and the extent to which our management uses judgment, assumptions, and estimates in applying these policies is integral to understanding our Financial Statements.
We describe our most significant accounting policies in Note 2, “Significant Accounting Policies” of our unaudited condensed consolidated notes to our Financial Statements beginning on page F-1 and found elsewhere in this report and in our 2019 Annual Report. These policies are considered critical because they may result in fluctuations in our reported results from period to period due to the significant judgments, estimates, and assumptions about highly complex and inherently uncertain matters. In addition, the use of different judgments, assumptions, or estimates could have a material impact on our financial condition or results of operations. We evaluate our critical accounting estimates and judgments required by our policies on an ongoing basis and update them as appropriate based on changing conditions.
There have been no material changes to our critical accounting policies during the period covered by this report.
Recent Accounting Pronouncements
We describe recent accounting pronouncements in Note 2, “Significant Accounting Policies” of our accompanying unaudited condensed consolidated notes to our Financial Statements beginning on page F-1.
5
The following table sets forth certain financial information from our unaudited condensed consolidated statements of operations along with a percentage of net revenue and should be read in conjunction with our Financial Statements and related notes included in this report.
|
|
For the Three Months Ended |
|
||||||||||
|
September 30, 2020 |
|
(% Rev) |
|
September 30, 2019 |
|
(% Rev) |
|
|||||
|
Net revenues |
$ |
5,738,662 |
|
100% |
|
$ |
5,716,344 |
|
100% |
|
||
|
Cost of revenues |
|
2,043,722 |
|
36% |
|
|
4,787,939 |
|
84% |
|
||
|
Gross profit |
|
3,694,940 |
|
64% |
|
|
928,405 |
|
16% |
|
||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general, administrative and other expenses |
|
1,379,385 |
|
24% |
|
|
2,263,964 |
|
40% |
|
||
|
Commissions |
|
2,185,487 |
|
38% |
|
|
1,741,770 |
|
31% |
|
||
|
Depreciation and amortization |
|
23,312 |
|
0% |
|
|
25,596 |
|
0% |
|
||
|
Total operating expenses |
|
3,588,184 |
|
63% |
|
|
4,031,330 |
|
71% |
|
||
|
Operating income\(loss) |
|
106,756 |
|
2% |
|
|
(3,102,925 |
) |
-54% |
|
||
|
Other expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
20,611 |
|
0% |
|
|
34,900 |
|
1% |
|
||
|
Total other expense |
|
20,611 |
|
0% |
|
|
34,900 |
|
1% |
|
||
|
Operating income (loss) before tax |
|
86,145 |
|
2% |
|
|
(3,137,825 |
) |
-55% |
|
||
|
Income tax benefit (expense) |
|
5,661 |
|
0% |
|
|
926,517 |
|
16% |
|
||
|
Net income\(loss) |
$ |
80,484 |
|
1% |
|
$ |
(4,064,342 |
) |
-71% |
|
||
Three Months Ended September 30, 2020, Compared to Three Months Ended September 30, 2019
Net Revenues
For the three months ended September 30, 2020, net revenues were $5,738,662 compared to $5,716,344 for the three months ended September 30, 2019, an increase of $22,318, or approximately 0.3%.
For the three months ended September 30, 2020, Retail Cases decreased by 3% compared to the three months ended September 30, 2019, offset by, revenues from Retail Cases for the three months ended September 30, 2020, increasing by 2% compared to revenues from Retail Cases for the three months ended September 30, 2019. We believe this 2% increase in revenues from Retail Cases is primarily driven by an increase in revenue per Retail Case.
Our Wholesale Cases decreased by 56% for the three months ended September 30, 2020, compared to Wholesale Cases during the three months ended September 30, 2019. Accordingly, revenues from Wholesale Cases for the three months ended September 30, 2020, decreased by 11% compared to revenues from Wholesale Cases for the three months ended September 30, 2019.
As discussed above in “Current Trends and Outlook,” we believe that as our industry faces increased pricing pressures, we will need to focus on increased volume of Cases to maintain gross profit levels. We will seek to increase our volume of Retail Case Sales to our existing retail customer base and add new retail customers.
Cost of Revenues
For the three months ended September 30, 2020, our cost of revenues was $2,043,722, compared to $4,787,939 for the three months ended September 30, 2019, representing a decrease of $2,744,217, or approximately 134.3%.
As a percentage of revenues, cost of revenues decreased approximately 48 percentage points to approximately 36% for the three months ended September 30, 2020, compared to approximately 84% for the three months ended September 30, 2019. The decrease as a percentage of net revenues resulted from (a)(i) an approximate 47% decrease in inventory shrink and inventory loss provision, (a)(ii) an approximate 4% reduction in cost of goods sold, offset, in part, by (b) an approximate 3% increase in medical instrument expense.
Gross Profit
For the three months ended September 30, 2020, we generated a gross profit of $3,694,940, compared to $928,405 for the three months ended September 30, 2019, representing an increase of $2,766,535 or approximately 298.0%.
As a percentage of net revenue, gross profit increased approximately 48 percentage points to 64% for the three months ended September 30, 2020, compared to 16% for the three months ended September 30, 2019. This increase in gross profit as a percentage of revenues was primarily caused by the decrease in cost of revenues as a percentage of net revenues, as discussed above.
6
Selling, General, Administrative, and Other Expenses
For the three months ended September 30, 2020, selling, general, administrative, and other expenses decreased to $1,379,385 from $2,263,964 for the three months ended September 30, 2019, representing a decrease of $884,579, or approximately 39.1%.
As a percentage of net revenues, selling, general, administrative and other expenses accounted for approximately 24% and 40% for the three months ended September 30, 2020 and September 30, 2019, respectively. As a percentage of net revenue, the decrease of approximately 16 percentage points primarily resulted from (a)(i) an approximate 9 percentage-point decline in provision for bad debt, (a)(ii) an approximate 5 percentage point decline in leased staffing costs, and (a)(iii) an approximate 4 percentage point decline in professional expense, offset, in part by, (b)(i) an approximate 2 percentage-point increase in stock based compensation. Reflected in professional fees and stock-based compensation was approximately $232,841 in compensation to members of our scientific advisory boards (“SABs”), of which approximately $150,000 was in the form of cash expense and approximately $82,841 was non-cash stock-based compensation. The three months ended September 30, 2020, reflected an approximate $112,500 decrease in professional fees related to the SABs as compared to the three months ended September 30, 2019.
Commissions
For the three months ended September 30, 2020 and September 30, 2019, commission expense was $2,185,487 and $1,741,770, respectively, representing an increase of $443,717, or approximately 25.5%.
As a percentage of net revenues, commission expense accounted for approximately 38% for the three months ended September 30, 2020, and 31% for the three months ended September 30, 2019. This approximate 7 percentage-point increase primarily resulted from an approximate 1% increase of revenues eligible for commissions and an approximate 6% increase in average commission rates.
Depreciation and amortization
For the three months ended September 30, 2020, our depreciation and amortization expense decreased to $23,312 from $25,596 for the three months ended September 30, 2019, representing a decrease of $2,284. This decrease is primarily driven by the complete amortization of the Company’s non-compete agreements.
Interest
For the three months ended September 30, 2020, interest expense declined to $20,611 from $34,900 for the three months ended September 30, 2019, which is a reduction of $14,289, or approximately 40.9%. The decline of $14,289 was primarily driven by (a)(i) an approximate $6,972 reduction in interest costs caused by a decline in LIBOR market interest rates, (a)(ii) an approximate $9,768 decrease in interest related to decreased borrowings on our RLOC, offset, in part, by (b)(i) an approximate $1,419 increase related to accrued interest on our EIDL Loan, (b)(ii) an approximate $907 increase related to accrued interest on our PPP Loan, and (b)(iii) an approximate $125 increase of accrued interest on our Subordinated Notes.
Income tax
For the three months ended September 30, 2020 and 2019, we recorded an income tax expense of approximately $5,661, and income tax expense $926,517. For additional information, please see Note 10, “Income Taxes,” of our accompanying Financial Statements, beginning on page F-1.
7
For the three months ended September 30, 2020, we had net income of $80,484 compared to a net loss of $4,064,342 for the three months ended September 30, 2019, respectively, representing an increase in net income of $4,144,826 or approximately 102.0%.
As a percentage of revenue, net income/(loss) represented approximately 1% and (71)% for the three months ended September 30, 2020 and September 30, 2019, respectively.
The approximate 72 percentage point increase in net income as a percentage of revenue was primarily attributable to (a)(i) an approximate 7 percentage point increase in commissions, offset, in part, by (b)(i) an approximate 16 percentage point decrease in income tax expense, (b)(ii) an approximate 16 percentage point decrease in selling, general, administrative, and other expenses, and (b)(iii) an approximate 48 percentage point decrease in cost of revenues.
Nine Months Ended September 30, 2020, Compared to Nine Months Ended September 30, 2019
Results of Operations
The following table sets forth certain financial information from our unaudited condensed consolidated statements of operations along with a percentage of net revenue and should be read in conjunction with our Financial Statements and related notes included in this report.
|
|
For the Nine Months Ended |
|
||||||||||
|
|
September 30, 2020 |
|
(% Rev) |
|
September 30, 2019 |
|
(% Rev) |
|
||||
|
Net revenues |
$ |
14,385,831 |
|
100% |
|
$ |
15,562,928 |
|
100% |
|
||
|
Cost of revenues |
|
5,823,281 |
|
40% |
|
|
8,987,196 |
|
58% |
|
||
|
Gross profit |
|
8,562,550 |
|
60% |
|
|
6,575,732 |
|
42% |
|
||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general, administrative and other expenses |
|
5,021,632 |
|
35% |
|
|
6,604,066 |
|
42% |
|
||
|
Commissions |
|
4,996,843 |
|
35% |
|
|
3,752,295 |
|
24% |
|
||
|
Depreciation and amortization |
|
84,047 |
|
1% |
|
|
76,916 |
|
0% |
|
||
|
Total operating expenses |
|
10,102,522 |
|
70% |
|
|
10,433,277 |
|
67% |
|
||
|
Operating loss |
|
(1,539,972 |
) |
-11% |
|
|
(3,857,545 |
) |
-25% |
|
||
|
Other expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
75,633 |
|
1% |
|
|
88,362 |
|
1% |
|
||
|
Total other expense |
|
75,633 |
|
1% |
|
|
88,362 |
|
1% |
|
||
|
Operating loss before tax |
|
(1,615,605 |
) |
-11% |
|
|
(3,945,907 |
) |
-25% |
|
||
|
Income tax benefit |
|
11,341 |
|
0% |
|
|
771,582 |
|
5% |
|
||
|
Net loss |
$ |
(1,626,946 |
) |
-11% |
|
$ |
(4,717,489 |
) |
-30% |
|
||
Net Revenues
For the nine months ended September 30, 2020, net revenues were $14,385,831 compared to $15,562,928 for the nine months ended September 30, 2019, a decrease of $1,177,097 or approximately 7.6%.
For the nine months ended September 30, 2020, Retail Cases decreased by 9% compared to the nine months ended September 30, 2019. Revenues from Retail Cases for the nine months ended September 30, 2020, increased by 2% compared to revenues from Retail Cases for the nine months ended September 30, 2019. This 2% increase in revenues from Retail Cases is primarily driven by greater concentration in new medical facilities.
Our Wholesale Cases decreased by 67% for the nine months ended September 30, 2020, compared to Wholesale Cases during the nine months ended September 30, 2019. Accordingly, revenues from Wholesale Cases for the nine months ended September 30, 2020, decreased by 47% compared to revenues from Wholesale Cases for the period ended September 30, 2019.
Cost of Revenues
For the nine months ended September 30, 2020, our cost of revenues was $5,823,281, compared to $8,987,196 for the nine months ended September 30, 2019, representing a decrease of $3,163,915, or approximately 35%.
As a percentage of revenues, cost of revenues decreased approximately 18 percentage points to approximately 40% for the nine months ended September 30, 2020, compared to approximately 58% for the nine months ended September 30, 2019. The decrease as a percentage of net revenues resulted from (a)(i) an approximate 12 percentage-point decrease in inventory shrink and inventory loss provision, (a)(ii)an approximate 7 percentage point reduction in cost of products sold, offset, in part, by (b)(i) an approximate 1 percentage point increase in medical instrument expense.
8
For the nine months ended September 30, 2020, we generated a gross profit of $8,562,550, compared to $6,575,732 for the nine months ended September 30, 2019, representing an increase of $1,986,818, or approximately 30.2%.
As a percentage of net revenue, gross profit increased by 18 percentage points to 60% for the nine months ended September 30, 2020, compared to 42% for the nine months ended September 30, 2019. This increase in gross profit as a percentage of revenues was primarily caused by the decrease in cost of revenues, as discussed above.
Selling, General, Administrative, and Other Expenses
For the nine months ended September 30, 2020, selling, general, administrative, and other expenses decreased to $5,021,632 from $6,604,066 for the nine months ended September 30, 2019, representing a decrease of $1,582,434, or approximately 24.0%.
As a percentage of net revenues, selling, general, administrative and other expenses accounted for approximately 35% and 42% for the nine months ended September 30, 2020 and September 30, 2019, respectively. As a percentage of net revenue, the decrease of approximately 7 percentage points primarily resulted from (a)(i) an approximate 3 percentage-point decline in the provision for bad debt, (a)(ii) an approximate 3 percentage point decline in leased staffing costs, and (a)(iii) an approximate 1 percentage point decrease in professional expense. Reflected in professional fees and stock-based compensation is approximately $1,240,469 in compensation to members of our SABs, of which approximately $800,000 was in the form of cash expense and approximately $440,469 was non-cash stock-based compensation. The nine months ended September 30, 2020, reflected an approximate reduction of approximately $250,000 in professional fees related to the SABs as compared to the nine months ended September 30, 2019.
Commissions
For the nine months ended September 30, 2020 and September 30, 2019, commission expense was $4,996,843 and $3,752,295, respectively, representing an increase of $1,244,548, or approximately 33.2%.
As a percentage of net revenues, commissions expenses accounted for approximately 35% for the nine months ended September 30, 2020, and 24% for the nine months ended September 30, 2019. This approximate 11 percentage-point increase primarily resulted from an approximate 3% increase of revenues eligible for commissions and approximately an 8% increase in average commission rates as well as the realignment and restructuring of the commission agreement for our largest commission-based representative.
Depreciation and amortization
For the nine months ended September 30, 2020, our depreciation expense increased to $84,047 from $76,916 for the nine months ended September 30, 2019, representing an increase of $7,131. This increase was primarily the result of an investment to upgrade our supply-chain inventory management system and new office workstations in prior periods.
Interest
For the nine months ended September 30, 2020, interest expense decreased to $75,633 from $88,362 for the nine months ended September 30, 2019, which is a decrease of $12,729, or approximately 14%. The decrease of $12,729 was primarily driven by (a)(i) an approximate $18,231 reduction in interest costs caused by a decline in the LIBOR market interest rates, offset, in part, by, (b)(i) an approximate $1,051 increase in interest related to increased borrowings on our RLOC, (b)(ii) an approximate $2,359 increase related to accrued interest on our EIDL Loan, (b)(iii) an approximate $1,810 increase related to accrued interest on our PPP Loan, and (b)(iv) an approximate $282 increase related to accrued interest on our Subordinated Notes.
Income tax
For the nine months ended September 30, 2020 and 2019, we recorded an income tax expense of approximately $11,341 and $771,582. For additional information, please see Note 10, “Income Taxes,” of our accompanying Financial Statements, beginning on page F-1.
9
For the nine months ended September 30, 2020, we had a net loss of $1,626,946 compared to a net loss $4,717,489 for the nine months ended September 30, 2019, respectively, representing a decrease in net loss of $3,090,543, or approximately 65%.
As a percentage of revenue, net loss represented approximately 11% and 30% for the nine months ended September 30, 2020 and September 30, 2019, respectively.
The approximate 19 percentage point decrease in net loss as a percentage of revenue was primarily attributable to (a)(i) an approximate 7 percentage point decrease in selling, general, administrative, and other expenses, (a)(ii) an approximate 5 percentage point reduction in income tax expense, and (a)(iii) an approximate 18 percentage point increase in gross profit, offset, in part, by (b)(i) an approximate 11 percentage point increase commissions.
Liquidity and Capital Resources
Cash Flows
A summary of our cash flows is as follows:
|
|
|
Nine Months Ended September 30, |
|
|||||
|
|
|
2020 |
|
|
2019 |
|
||
|
Net cash provided by (used in) operating activities |
|
$ |
463,084 |
|
|
$ |
(88,097 |
) |
|
Net cash used in investing activities |
|
|
(20,757 |
) |
|
|
- |
|
|
Net cash used in financing activities |
|
|
(2,749 |
) |
|
|
275,053 |
|
|
Net increase in cash and cash equivalents |
|
$ |
439,578 |
|
|
$ |
186,956 |
|
Net Cash Provided by (Used in) Operating Activities
During the nine months ended September 30, 2020, net cash provided by operating activities was $463,084 compared to $88,097 used in operating activities for the nine months ended September 30, 2019, representing an increase of $551,181.
For the nine months ended September 30, 2020, our net cash provided by operating activities resulted primarily from: (a)(i) a $1,848,178 decrease in accounts receivable, (a)(ii) a $872,971 reduction in inventories, (a)(iii) a $219,035 increase in accrued expenses, and (a)(iv) a $4,891 decrease in prepaid expenses and other current assets, offset, in part by (b)(i) an increase of $1,908,403 of long term accounts receivable, (b)(ii) a $409,371 reduction in accounts payable, and (b)(iii) a $164,216 of net loss adjusted for non-cash items.
For the nine months ended September 30, 2019, our net cash used in operating activities resulted primarily from: (a)(i) $2,312,419 of net loss adjusted for non-cash items (a)(ii) an increase of $774,712 in long term accounts receivable, and (a)(iii) a $186,823 reduction in accounts payable, net, offset, in part, by (b)(i) a $2,886,268 decrease in inventories, (b)(ii) a $161,943 decrease in accounts receivable, (b)(iii) a $125,458 increase in accrued liabilities, and (b)(iv) a $12,188 decrease in prepaid expenses.
Net Cash Used in Investing Activities
During the nine months ended September 30, 2020, net cash used in investing activities was approximately $20,757 for our investments in (i) new office workstations and (ii) equity incentive plan administrative and tracking software.
For the nine months ended September 30, 2019, there was no net cash used in investing activities.
Net Cash Used in Financing Activities
For the nine months ended September 30, 2020, net cash used in financing activities was $2,749, compared to the $275,053 provided by financing activities for the nine months ended September 30, 2019.
The $2,749 in net cash used in financing activities for the nine months ended September 30, 2020 primarily resulted from (a)(i) $361,400 in proceeds from our PPP Loan, (a)(ii) $200,000 in proceeds from our Subordinated Notes; and (a)(iii) $150,000 in proceeds from our EIDL Loan, offset by (b)(i) $714,149 in net repayments on our RLOC.
The $275,053 in net cash provided by financing activities for the nine months ended September 30, 2019 resulted from borrowings on our RLOC.
10
Our primary sources of liquidity are cash from our operations and our RLOC with Amegy Bank. As of September 30, 2020, our current assets exceeded our current liabilities by $4,345,261 (our “Working Capital”), which includes $1,538,888 in cash and cash equivalents. We believe cash from our operations and net borrowings on our RLOC supports our Working Capital needs.
Effective December 31, 2017, we became party to the RLOC with Amegy Bank. The RLOC established an asset-based senior secured revolving credit facility with contractual aggregate limit of $5,000,000. The RLOC contains customary representation, warranties, covenants, events of default, and is collateralized by substantially all of our assets and provides that our Chairman of the Board of Directors (“Board”) and President provides a personal guarantee for a portion of the outstanding RLOC amount.
On September 21, 2018, we executed the First Amendment to the RLOC with Amegy Bank (the “First Amendment”). The First Amendment (i) waived our events of default under the RLOC through the fiscal quarter ended September 30, 2018, and (ii) added a covenant that we achieve quarterly net income of $700,000 or more for the fiscal quarter ending on September 30, 2018.
On November 19, 2018, we executed the Second Amendment to the RLOC with Amegy Bank (the “Second Amendment”). The Second Amendment (i) waived our events of default under the RLOC, (ii) reduced the aggregate contractual limit of the RLOC to $4,000,000, (iii) extended the maturity date to November 4, 2019, (iv) revised the variable interest rate to the one-month LIBOR rate plus four percent (4.00%) per annum, and (v) amended the financial covenants to state that we will not permit (i) the Fixed Charge Coverage Ratio of any calendar quarter end from and after the quarter ending June 30, 2019, to be less than 1.25 to 1.00; (ii) earnings before interest, taxes, depreciation and amortization (“EBITDA”) to be less than $700,000 for the fiscal quarter ending December 31, 2018, and $100,000 for the fiscal quarter ending March 31, 2019; and (iii) modified the event of default related to consecutive quarterly losses to be applicable from and after the quarter ending June 30, 2019.
On May 9, 2019, we executed the Third Amendment to the RLOC with Amegy Bank (the “Third Amendment”). Pursuant to the Third Amendment, Amegy Bank (i) waived our events of default under the RLOC, (ii) reduced the aggregate contractual limit of the RLOC to $3,500,000, (iii) reduced the limit of credit card exposure to $500,000, (iv) reduced the borrowing base component of Inventory to 30%, (v) amended the financial covenants to state that we will not permit EBITDA to be less than $100,000 for the fiscal quarter ending June 30, 2019 and $500,000 for the fiscal quarter ending September 30, 2019, and (vi) rescinded the loan sweep feature, requiring us to give notice of each requested loan by delivery of advance request to Amegy Bank.
On December 18, 2019, we executed the Fourth Amendment to the RLOC with Amegy Bank (the “Fourth Amendment”). Pursuant to the Fourth Amendment, Amegy Bank (i) waived our events of default under the RLOC, (ii) reduced the aggregate contractual limit of the RLOC to $2,750,000, (iii) reduced and limited the annual salary of our Chairman of the Board and President, Mr. Brooks, to not exceed $550,000, (iv) amended the financial covenants to state that we will not permit EBITDA to be less than $600,000 for the fiscal quarter ending December 31, 2019 and $125,000 for the fiscal quarter ending March 31, 2020, (v) extended the termination date of the RLOC to May 4, 2020, and (vi) provided that our Chairman of the Board and President provides a personal guarantee for one-hundred percent (100%) of the outstanding RLOC amount.
On May 21, 2020, we executed the Fifth Amendment to our RLOC with Amegy Bank (the “Fifth Amendment”). Pursuant to the Fifth Amendment, Amegy Bank (i) waived our events of default under the RLOC, (ii) amended the financial covenants to state that we will not permit EBITDA to be less than $25,000 for the fiscal quarters ending June 30, 2020 and September 30, 2020, and (iii) extended the termination date of our RLOC until November 4, 2020.
In conjunction with obtaining the Fifth Amendment, we obtained an additional $200,000 in capital in the form of subordinated debt from affiliates of Messrs. Brooks and Reeg. Specifically, on May 6, 2020, we borrowed $180,000 from NC 143, a limited partnership controlled by Mr. Brooks, and $20,000 from RMI, a company owned and controlled by Mr. Reeg, in exchange for two promissory notes which are unsecured and bear interest at 0.25% per annum until May 6, 2022, the maturity date, and 10.0% per annum after the maturity date. Principal and interest are due and payable on the maturity date, provided, however, any payment of principal and interest on the loans is subordinated to payment of all indebtedness under the RLOC.
For the three months ended September 30, 2020, we were in compliance with the covenants of our RLOC with Amegy Bank. On November 12, 2020 we executed a Sixth Amendment to the RLOC with Amegy Bank, which extended the termination date of our RLOC to May 4, 2021. (See Note 5, “Senior Secured Revolving Credit Facility” of our accompanying unaudited condensed consolidated notes to our Financial Statements, beginning on page F-1).
We rely on our RLOC for capital expenditures and other day-to-day Working Capital needs. As of November 5, 2020, we had approximately $1,186,674 in available cash, and $528,667 available on our RLOC for borrowing (subject to certain borrowing base limitations). Borrowings on our RLOC are repaid from cash generated from our operations.
11
Payroll Protection Program
On April 11, 2020, we received approval from the SBA to fund our request for a PPP Loan created as part of the recently enacted CARES Act administered by the SBA. In connection with the PPP Loan, we entered into a promissory note in the principal amount of $361,400. In accordance with the requirements of the CARES Act, we intend to use the proceeds from the PPP Loan primarily for payroll costs. The PPP Loan is reflected in short term liabilities in our accompanying interim unaudited condensed consolidated balance sheets on F-1 as we expect the PPP Loan will be forgiven during 2020.
Economic Injury Disaster Loan
On May 12, 2020, we executed the standard loan documents required for securing a EIDL Loan from the SBA in light of the impact of the COVID-19 pandemic on our business. Pursuant to that certain Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan was $150,000, with proceeds to be used for working capital purposes. In connection therewith, we received a $10,000 advance, which does not have to be repaid and is reflected as an offset in Selling, General, Administrative and Other Expenses in our accompanying interim unaudited condensed consolidated statements of operations.
(See Note 8, “Economic Injury Disaster Loan” of our accompanying unaudited condensed consolidated notes to our Financial Statements, beginning on page F-1).
Going Concern
The accompanying interim unaudited condensed consolidated financial statements have been prepared as if we will continue as a going concern. Through September 30, 2020, we had accumulated losses of $4,222,759 and a stockholders’ deficit of $2,420,164. Although revenue increased by $22,318, or less than 1% in the third quarter of 2020 versus the same quarter in 2019, as we have been impacted by restrictions as a result of the COVID-19 pandemic throughout 2020. At various times during 2018 and 2019, and for the first quarter ended March 31, 2020, we were out of compliance with one or more covenants contained in our RLOC, but obtained waivers from Amegy Bank to cure the violations, along with reductions in our aggregate contractual borrowing limits under our RLOC. On November 12, 2020, we executed a Sixth Amendment to the RLOC with Amegy Bank, which extended the termination date of our RLOC to May 4, 2021. We have determined that these conditions and events raise substantial doubt about our ability to continue as a going concern.
Our ability to continue as a going concern for at least one year beyond the date of this filing is dependent upon the easing of restrictions imposed on elective surgeries by civil authority as a result of COVID-19, as well as our (i) successful execution of key branding initiatives, (ii) introduction, commercialization and sales of new proprietary products and product lines, (iii) increased sales of existing products, with strategic emphasis on selling more Retail Cases and increasing the percentage of Retail Cases sold as a percentage of all Cases we sell, and (iv) continued cost reductions. Additionally, we will need to refinance our RLOC with Amegy Bank, which is set to expire on May 4, 2021, with a new credit facility on commercially reasonable terms or obtain equity financing. We were in compliance with all covenants contained in our RLOC with Amegy Bank as of Septembers 30, 2020.
Our accompanying interim unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should we be unable to continue as a going concern.
Capital Expenditures
For the nine months ended September 30, 2020, we had no material commitments for capital expenditures.
Off-Balance Sheet Arrangements
For the nine months ended September 30, 2020, we had no off-balance sheet arrangements.
Cautionary Note Regarding Forward-Looking Statements
This report includes forward-looking statements including statements regarding liquidity.
The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect”, and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs.
12
The results anticipated by any of these forward-looking statements might not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include; the conditions of the capital markets, particularly for smaller companies; the willingness of doctors and facilities to purchase the products that we sell; certain regulatory issues adversely affecting our margins; insurance companies denying reimbursement to facilities who use the products that we sell; and our ability to sell products. We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events, or otherwise.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
As a “smaller reporting company” as defined by Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this item.
ITEM 4. CONTROLS AND PROCEDURES.
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports, that are filed or submitted under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that this information is accumulated and communicated to management, including the principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
We conducted an evaluation (pursuant to Rule 13a-15(b) promulgated under the Exchange Act), under the supervision and with the participation of management, including our Chief Executive and Chief Financial Officers, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) promulgated under the Exchange Act) as of September 30, 2020.
Based on our evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were effective as of September 30, 2020.
13
On November 12, 2020, we executed the Sixth Amendment to our RLOC with Amegy Bank, which extended the termination date of the RLOC until May 4, 2021. The Sixth Amendment is attached hereto as Exhibit 10.1. (See Note 5, “Revolving Line of Credit” and Note 13, “Subsequent Events” of our unaudited condensed consolidated notes to our Financial Statements beginning on page F-1).
See the exhibits listed in the accompanying “Exhibit Index”.
14
|
|
Description |
|
|
|
|
|
|
|
|
|
|
3.1 |
|
|
|
|
|
|
|
3.2 |
|
|
|
|
|
|
|
10.1* |
|
|
|
|
|
|
|
31.1* |
|
|
|
|
|
|
|
|
|
|
|
31.2* |
|
|
|
|
|
|
|
|
|
|
|
32.1** |
|
|
|
|
|
|
|
|
|
|
|
101.INS * |
|
XBRL Instance Document |
|
|
|
|
|
101.SCH * |
|
XBRL Taxonomy Extension Schema Document |
|
|
|
|
|
|
|
|
|
101.CAL * |
|
XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
|
|
|
|
|
|
|
101.DEF * |
|
XBRL Taxonomy Extension Definition Linkbase Document |
|
|
|
|
|
|
|
|
|
101.LAB * |
|
XBRL Taxonomy Extension Label Linkbase Document |
|
|
|
|
|
|
|
|
|
101.PRE * |
|
XBRL Taxonomy Extension Presentation Linkbase Document |
|
* |
Filed herewith. |
|
** |
Furnished herewith |
15
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
FUSE MEDICAL, INC. |
|
||
|
|
|
|
|
|
Date: November 16, 2020 |
By: |
/s/ Christopher C. Reeg |
|
|
|
|
Christopher C. Reeg |
|
|
|
|
Chief Executive Officer and Director (Principal Executive Officer) |
|
|
Date: November 16, 2020 |
By: |
/s/ William E. McLaughlin, III |
|
|
|
|
William E. McLaughlin, III |
|
|
|
|
Senior Vice President, Chief Financial Officer and Director (Principal Financial Officer) |
|
16
Execution Version
SIXTH AMENDMENT TO AMENDED
AND RESTATED BUSINESS LOAN AGREEMENT
This SIXTH AMENDMENT TO AMENDED AND RESTATED BUSINESS LOAN
AGREEMENT (this “Amendment"), dated November 12, 2020 (the "Amendment Effective Date"), is made and entered into by and among Zions Bancorporation, N.A. dba Amegy Bank (together with its successors and assigns, "Lender"), Fuse Medical , Inc . ("Fuse") and CPM Medical Consultants, LLC ("CPM", together with Fuse, collectively, the "Borrowers" and each a "Borrower").
RECITALS
|
|
A. |
Lender and Borrowers are parties to that certain Amended and Restated Business Loan Agreement dated as of December 31, 20 I 7 (as amended by that certain Limited Wavier and First Amendment to Amended and Restated Business Loan Agreement, dated as of September 21, 2018, as amended by that certain Limited Waiver and Second Amendment to Amended and Restated Business Loan Agreement, dated as of November 19, 2018, as amended by that certain Limited Waiver and Third Amendment to Amended and Restated Business Loan Agreement dated as of May 9, 2019 , as amended by that certain Limited Waiver and Fourth Amendment to Amended and Restated Business Loan Agreement dated December 18, 2019, as amended by that certain Limited Waiver and Fifth Amendment to Amended and Restated Business Loan Agreement dated May 21, 2020, and as may be further amended, restated , amended and restated , supplemented or otherwise modified from time to time, the "Loan Agreement") . |
|
B.Lender is willing to amend the Loan Agreement on the tem1s and subject to the condition s set forth below .
NOW, THEREFORE, in consideration of the premises herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
ARTICLE I
Definitions
Section 1.1 Definitions. Capitalized terms used in this Amendment, to the extent not otherwise defined herein , shall have the same definitions assigned to such terms in the Loan Agreement, as amended hereby .
ARTICLE II
Reserved ARTICLE III
Amendments to the Loan Agreement
In reliance upon the representations and warranties of the Lender and Borrowers set forth in the Loan Documents and in this Amendment , the Loan Agreement is hereby amended, effective as of the Amendment Effective Date, as follows :
-1-
SMRH :4837-331 5 - 2721 .4
Section 3.1Amendments.
(a)The following definition in Section 1.1 of the Loan Agreement is hereby amended and restated in its entirety as follows :
"Termination Date" means May 4, 2021.
|
|
(b) |
Section 9.1(b) of the Loan Agreement is hereby amended and restated to read in its entirety as follows: |
|
"(b) Minimum EBITDA. Borrowers shall not permit EBITDA to be less than (i) $600,000 for the trailing nine (9) month period ending December 31, 2020,
|
|
(ii) |
$600,000 for the trailing twelve (12 ) month period ending March 31, 2021 and (iii) $600,000 for each trailing twelve (12) month period ending on each calendar quarter thereafter ." |
|
ARTICLE IV
Conditions Precedent
Section 4.1 Conditions Precedent. The effectiveness of this Amendment is subject to the satisfaction of the following conditions precedent, unless specifically waived in writing by Lender:
(a)Lender shall have received a counterpart of this Amendment duly executed by Borrowers and the Consent and Reaffirmation duly executed by Guarantors;
(b)the representations and warranties contained herein and in all other Loan Documents shall be true and correct as of the Amendment Effective Date as if made on the Amendment Effective Date;
|
|
(c) |
no Default or Event of Default shall have occurred and be continuing; |
(d)Borrowers shall have paid all reasonable costs and expenses incurred by Lender in connection with the preparation, negotiation and execution of this Amendment and the other Loan Documents executed pursuant hereto , including, without limitation , the costs and fees of Lender' s legal counsel and such counsel' s outstanding invoices related to the preparation of the Loan Documents and amendments thereto ;
ARTICLE V
Ratifications Representations Warranties Acknowledgments and Covenants
Section 5.1 Ratifications by Borrowers. The terms and provisions set forth in this Amendment shall modify and supersede all inconsistent terms and provisions set forth in the Loan Agreement and, except as expressly modified and superseded by this Amendment , the terms and provisions of the Loan Agreement are ratified and confirmed and shall continue in full force and effect. The Loan Agreement as amended by this Amendment shall continue to be legal, valid, binding and enforceable in accordance with its terms.
Section 5.2 Renewal and Extension of Security Interests and Liens. Each Borrower hereby
(a) renews and affirms the Liens created and granted in the Loan Documents , and (b) agrees that this Amendment shall in no manner affect or impair the Liens securing the Obligations, and that such Liens shall not in any manner be waived, the purposes of this Amendment being to modify the Loan Agreement
-2-
SMRH :4837-331 5 - 2721 .4
as herein provided, and to carry forward all Liens securing the same, which are acknowledged by such Borrower to be valid and subsisting .
Section 5.3 Representations and Warranties. Each Borrower represents and warrants to Lender that (a) the execution, delivery and performance of this Amendment and any and all Loan Documents executed and/or delivered in connection herewith have been authorized by all requisite entity action on the part of such Borrower and will not violate the organizational documents of such Borrower or any agreement to which such Borrower is a party, (b) the representations and warranties contained in the Loan Agreement and in each of the other Loan Documents are true and correct on and as of the Amendment Effective Date as though made on the Amendment Effective Date, (c) no Default or Event of Default under the Loan Agreement has occurred and is continuing, and (d) such Borrower is in full compliance with all covenants and agreements contained in the Loan Agreement , as amended hereby.
ARTICLE VT
Miscellaneous
Section 6.1 Survival of Representations and Warranties. All representations and warranties made in the Loan Agreement or any other Loan Document, including without limitation, any Loan Document furnished in connection with this Amendment, shall survive the execution and delivery of this Amendment and the other Loan Documents, and no investigation by Lender or any closing shall affect such representations and warranties or the right of Lender to rely thereon .
Section 6.2 Reference to Loan Agreement. Each of the Loan Documents and any and all other agreements, documents or instruments now or hereafter executed and delivered pursuant to the terms hereof or pursuant to the terms of the Loan Agreement as amended hereby , are hereby amended so that any reference in such Loan Documents to the Loan Agreement shall mean a reference to the Loan Agreement as amended hereby.
Section 6.3 Expenses of Lender. Borrowers agree to pay on demand all reasonable costs and expenses incurred by Lender directly in connection with any and all amendments, modifications, and supplements to this Amendment and the other Loan Documents executed pursuant hereto, including , without limitation, the costs and fees of Lender 's legal counsel, and all costs and expenses incurred by Lender in connection with the enforcement or preservation of any rights under the Loan Agreement, as amended hereby , or any other Loan Document , including, without limitation, the reasonable costs and fees of Lender's legal counsel.
Section 6.4 Severability. Any provision of this Amendment held by a court of competent jurisdiction to be invalid or unenforceable shall not impair or invalidate the remainder of this Amendment and the effect there o f shall be confined to the provision so held to be invalid or unenforceable .
Section 6.5 APPLICABLE LAW. THIS AMENDMENT SHALL BE DEEMED TO HAVE BEEN MADE AND TO BE PERFORMABLE IN AND SHALL BE GOVERNED BY A D CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS NOT INCLUDING CONFLICTS OF LAW RULES.
Section 6.6 WAIVER OF JURY TRIAL. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE PARTIES HERETO EACH HEREBY WAIVES THE RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT, COUNTERCLA IM, OR PROCEEDING ARISING OUT OF OR RELATED TO THIS AMENDMENT.
-3-
SMRH :4837-331 5 - 2721 .4
Section 6.7 RELEASE OF CLAIMS. TO INDUCE LENDER TO ENTER INTO THIS AMENDMENT, EACH BORROWER , AND BY GUARANTORS' SIGNATURES TO THE CO SENT AND REAFFIRMATION, EACH GUARANTOR VOLUNTARILY , KNOWINGLY AND UNCONDITIONALLY RELEASES , ACQUITS , AND FOREVER DISCHARGES LENDER AND ITS OFFICERS, DI RECTORS , AGENTS , EMPLOYEES, SUCCESSORS , AND ASSIGNS (COLLECTIVELY , THE "RELEASED PARTIES"), FROM ANY AND ALL LIABILITIES, CLAIMS, DEMANDS, DAMAGES, EXPENSES, ACTIONS, OR CAUSES OF ACTION OF ANY KIND OR NATURE (IF THERE BE ANY) , WHETHER ABSOLUTE OR CONTINGENT, DISPUTED OR UNDISPUTED, AT LAW OR IN EQUITY, OR KNOWN OR UNKNOWN, THAT SUCH BORROWER NOW HAS OR EVER HAD AGAINST ANY OF THE RELEASED PARTIES ARISING UNDER OR IN CONNECTION WITH ANY OF THE LOAN DOCUMENTS OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, ANY SUCH LIABILITIES, CLAIMS, DEMANDS, DAMAGES, EXPENSES, ACTIONS , OR CAUSES OF ACTION ARISING OUT OF OR RELATING TO A CLAIM OF BREACH OF CONTRACT, FRAUD, LENDER LIABILITY OR MIS CONDUCT, BREACH OF FIDUCIARY DUTY, USURY, UNFAIR BARGAINING POSITION, UNCONSCIONABILITY , VIOLATION OF LAW, NEGLIGENCE , ERROR OR OMISSION IN ACCOUNTING OR CALCULATIONS, MISAPPROPRIATION OF FUNDS, TORTIOUS CONDUCT OR RECKLESS OR WILLFUL MISCONDUCT. EACH BORROWER AND EACH GUARANTOR REPRESENTS AND WARRANTS TO LENDER THAT IT HAS NOT TRANSFERRED OR ASSIGNED TO ANY PERSON ANY CLAIM THAT IT HAS EVER HAD OR CLAIMED TO HAVE AGAINST ANY RELEASED PARTY .
Section 6.8 Successors and Assigns. This Amendment is binding upon and shall inure to the benefit of the parties hereto and their respective successors, assigns , heirs, executors, and legal representatives, except that none of the parties hereto other than Lender may assign or transfer any of its rights or obligations hereunder without the prior written consent of Lender.
Section 6.9 Counterparts. This Amendment may be executed in one or more counterparts , each of which when so executed shall be deemed to be an original , but all of which when taken together shall constitute one and the same instrument. Any signature delivered by a party by facsimile or other electronic transmission shall be deemed to be an original signature hereto .
Section 6.10 Effect of Waiver. No consent or waiver, express or implied, by Lender to or for any breach of or deviation from any covenant, condition or duty by any Borrower, shall be deemed a consent to or waiver of any other breach of the same or any other covenant , condition or duty.
Section 6.11 Headings. The headings , captions, and arrangements used in this Amendment are for convenience only and shall not affect the interpretation of this Amendment.
Section 6.1 2 Conflicting Provision. If any provision of the Loan Agreement as amended hereby conflicts with any provision of any other Loan Document , the provision in the Loan Agreement shall control.
Section 6.13 ENTIRE AGREEMENT. THIS AMENDMENT , THE LOAN AGREEMENT AND ALL OTHER LOAN DOCUMENTS EXECUTED AND DELIVERED IN CONNECTION WITH AND PURSUANT TO THIS AMENDMENT AND THE LOAN AGREEMENT REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES .
[Signature Pages Follow]
-4-
SMRH :4837-331 5 - 2721 .4
IN WITNESS WHEREOF, the parties hereto have caused this Sixth Amendment to be duly executed and delivered as of the date first written above.
BORROWER:
FUSE MEDICAL, INC
By: /s/ Christopher C. Reeg
Name: Christopher C. Reeg
Title: Chief Executive Officer
BORROWER:
CPM MEDICAL CONSULTANTS, LLC
By: /s/ Christopher C. Reeg
Name: Christopher C. Reeg
Title: Chief Executive Officer
LENDER:
ZIONS BANCORPORATION, N.A. dba AMEGY
BANK
By: /s/ Nicholas Diaz
Name: Nicholas Diaz
Title: Executive Vice President
CONSENT AND REAFFIRMATION
Each of the undersigned guarantors acknowledges that Zions Bancorporation , N.A. dba Amegy Bank) ("Lender") has no obligation to provide it with notice of, or to obtain its consent to, the terms of the foregoing Sixth Amendment to the Amended and Restated Business Loan Agreement (the "Amendment"). Nevertheless , each of the under signed consents to the Amendment and other Loan Documents effected thereby, agrees to be bound thereby and confim1s and agrees that, notwithstanding the effectiveness of the Amendment , each Loan Document to which the undersigned is a party is, and the obligations thereunder to which it is a party are, and shall continue to be, in full force and effect and are hereby ratified and confirmed in all respects, in each case as amended by the Amendment.
GUA RANTORS :
NC 143 FAMILY HOLDINGS LP
|
|
By: |
NC 143 Family Holdings GP LLC, General Partner of NC 14 3 Family Holdings LP |
|
|
|
By: |
NC 143 Family Trust, Dated October 1, 2014, as last amended, Manager of NC 143 Family Holding s GP LLC |
|
By: /s/ Mark W. Brooks
Name: Mark W. Brooks
Title: Trustee of NC 143 Family Trust
By: /s/ Penelope A. Brooks
Name: Penelope A. Brooks
Title: Trustee of NC 143 Family Trust
MARK W. BROOKS
By: /s/ Mark W. Brooks
EXHIBIT 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
I, Christopher C. Reeg, certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q of Fuse Medical, Inc.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
c) |
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
d) |
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
|
5. |
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
|
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|
|
|
|
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
|
Date: November 16, 2020 |
By: |
/s/ Christopher C. Reeg |
|
|
|
Christopher C. Reeg |
|
|
|
Chief Executive Officer |
EXHIBIT 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
I, William E. McLaughlin, III, certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q of Fuse Medical, Inc.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
c) |
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
d) |
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
|
5. |
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
|
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
|
Date: November 16, 2020 |
By: |
/s/ William E. McLaughlin, III |
|
|
|
William E. McLaughlin, III |
|
|
|
Senior Vice President, Chief Financial Officer |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Fuse Medical, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof, I, Christopher C. Reeg, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
|
|
1. |
The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and |
|
|
2. |
The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Dated: November 16, 2020 |
By: |
/s/ Christopher C. Reeg |
|
|
|
Christopher C. Reeg |
|
|
|
Chief Executive Officer |
In connection with the quarterly report of Fuse Medical, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof, I, William E. McLaughlin, III, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
|
|
1. |
The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and |
|
|
2. |
The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Dated: November 16, 2020 |
By: |
/s/ William E. McLaughlin, III |
|
|
|
William E. McLaughlin, III |
|
|
|
Senior Vice President, Chief Financial Officer |